How many Vinorelbine clinical trials are there?

426 Vinorelbine clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 30 are actively recruiting participants. 214 are marked completed.

Are Vinorelbine clinical trials recruiting in 2026?

Yes — 30 Vinorelbine trials are actively recruiting in 2026, with 191 U.S. sites across 38 states. See the recruiting trials and the per-state site list further down this page.

What conditions is Vinorelbine being studied for?

Vinorelbine is being studied for Breast Cancer, Lung Cancer, Metastatic Breast Cancer, Non Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung and 358 more. The trials are grouped by indication on this page.

What phase is Vinorelbine in?

Vinorelbine clinical trials span 7 Phase 4, 103 Phase 3, 225 Phase 2, 40 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Vinorelbine clinical trials?

The lead sponsor across the most Vinorelbine trials is Fudan University, with 222 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Vinorelbine Clinical Trials (2026): 426 Studies for Breast Cancer & Lung Cancer

Creator: Hipa.ai Research
Published: 2026-05-26T17:40:36.902Z

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: August 31, 2026.

426 Vinorelbine clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 160 indications (including Breast Cancer & Lung Cancer) and 67,114 total planned enrollment. 103 Phase 3 Vinorelbine trials and 225 Phase 2, 7 Phase 4 are listed. 37 Vinorelbine clinical trials are actively recruiting at 191 U.S. sites across 38 states. Most recent activity: NCT06023641 (Oct 2037).

Where to Participate: All Vinorelbine Trial Sites in the U.S. (191 sites across 38 states)

Every actively recruiting Vinorelbinetrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AL	Children's Hospital of Alabama	Birmingham35233	NCT07466316	Map
AL	USA Health Strada Patient Care Center	Mobile36604	NCT07466316	Map
AZ	Mayo Clinic Scottsdale - PPDS	Phoenix85054	NCT06435429	Map
AZ	Phoenix Children's Hospital	Phoenix85016	NCT05999994	Map
AZ	Phoenix Children's Hospital	Phoenix85016	NCT05999994	Map
AZ	The University of Arizona Cancer Center - North Campus	Tucson85719	NCT07007559	Map
AZ	University of Arizona Cancer Center	Tucson85719	NCT06435429	Map
AR	Arkansas Children's Hospital	Little Rock72202-3591	NCT07466316	Map
CA	The Oncology Institute Of Hope And Innovation	Cerritos90703	NCT06435429	Map
CA	City of Hope	Duarte91010	NCT07007559	Map
CA	City of Hope Comprehensive Cancer Center	Duarte91010	NCT07466316	Map
CA	Los Angeles Hematology Oncology Medical Group Glendale	Glendale91204	NCT06435429	Map
CA	UC San Diego Moores Cancer Center	La Jolla92037	NCT07007559	Map
CA	Loma Linda University Medical Center	Loma Linda92354	NCT07466316	Map
CA	Cedars-Sinai Medical Center	Los Angeles90048	NCT07466316	Map
CA	Mattel Children's Hospital UCLA	Los Angeles90095	NCT07466316	Map
CA	USC-Norris Comprehensive Cancer Center - Investigational Drug Service IDS	Los Angeles90033	NCT06435429	Map
CA	Valley Children's Hospital	Madera93636	NCT07466316	Map
CA	Kaiser Permanente-Oakland	Oakland94611	NCT07466316	Map
CA	Children's Hospital of Orange County	Orange92868	NCT07466316	Map
CA	Children's Hospital of Orange County	Orange92868	NCT05999994	Map
CA	UC Irvine Health - Chao Family Comprehensive Cancer Center	Orange928686	NCT07007559	Map
CA	Stanford University	Palo Alto94304	NCT06023641	Map
CA	UCSF at Mission Bay MB	San Francisco94158	NCT06435429	Map
CA	University of California, San Francisco	San Francisco94143	NCT07021989	Map
CO	Children's Hospital Colorado	Aurora80045	NCT07466316	Map
CO	University of Colorado-Cancer Center-PPDS	Aurora80045-2517	NCT06435429	Map
CO	Children's Hospital of Colorado	Denver80218	NCT05999994	Map
CO	Rocky Mountain Cancer Centers	Denver80218	NCT06435429	Map
CO	Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center	Denver80218	NCT07466316	Map
CO	Saint Joseph Hospital - Cancer Centers of Colorado	Denver80218	NCT07007559	Map
CO	Lutheran Hospital - Cancer Centers of Colorado	Golden80401	NCT07007559	Map
CO	Saint Mary's Regional Hospital - Cancer Centers of Colorado	Grand Junction81501	NCT07007559	Map
CT	Connecticut Children's Medical Center	Hartford06106	NCT07466316	Map
DE	Alfred I duPont Hospital for Children	Wilmington19803	NCT07466316	Map
DC	Children's National Medical Center	Washington D.C.20010	NCT05999994	Map
DC	Medstar Georgetown University Hospital	Washington D.C.20007	NCT06435429	Map
DC	The George Washington Medical facility Associates	Washington D.C.20037	NCT07007559	Map
DC	Washington Cancer Center	Washington D.C.20010	NCT06435429	Map
FL	Florida Cancer Specialists Research South	Fort Myers33901	NCT06435429	Map
FL	Golisano Children's Hospital of Southwest Florida	Fort Myers33908	NCT07466316	Map
FL	Golisano Children's Hospital of Southwest Florida	Fort Myers33908	NCT05999994	Map
FL	Memorial Regional Hospital/Joe DiMaggio Children's Hospital	Hollywood33021	NCT07466316	Map
FL	Mayo Clinic in Florida	Jacksonville32224	NCT05999994	Map
FL	Mayo Clinic Jacksonville - PPDS	Jacksonville32224	NCT06435429	Map
FL	Nemours Children's Clinic-Jacksonville	Jacksonville32207	NCT07466316	Map
FL	Sylvester Comprehensive Cancer Center	Miami33136	NCT07007559	Map
FL	University of Miami	Miami33136	NCT03618550	Map
FL	Nemours Children's Hospital	Orlando32827	NCT07466316	Map
FL	Nemours Children's Clinic - Pensacola	Pensacola32504	NCT07466316	Map
FL	Florida Cancer Specialists Research North	St. Petersburg33705	NCT06435429	Map
FL	Johns Hopkins All Children's Hospital	St. Petersburg33701	NCT07466316	Map
FL	Moffitt Cancer Center	Tampa33612	NCT06875128	Map
FL	Florida Cancer Specialists Research East	West Palm Beach33401	NCT06435429	Map
FL	Saint Mary's Medical Center	West Palm Beach33407	NCT07466316	Map
GA	Children's Healthcare of Atlanta - Arthur M Blank Hospital	Atlanta30329	NCT07466316	Map
IL	Ann & Robert H Lurie Children's Hospital of Chicago	Chicago60611	NCT05999994	Map
IL	Lurie Children's Hospital-Chicago	Chicago60611	NCT07466316	Map
IL	University of Illinois	Chicago60612	NCT07466316	Map
IL	University of Illinois Cancer Center	Chicago60612	NCT06576635	Map
IL	City of Hope Chicago	Zion60099	NCT07007559	Map
IN	Riley Hospital for Children	Indianapolis46202	NCT07466316	Map
IA	Blank Children's Hospital	Des Moines50309	NCT07466316	Map
KS	Wesley Medical Center	Wichita67214	NCT07466316	Map
KY	Norton Children's Hospital	Louisville40202	NCT07466316	Map
ME	MaineHealth Coastal Cancer Treatment Center	Bath04530	NCT07466316	Map
ME	MaineHealth Maine Medical Center - Portland	Portland04102	NCT07466316	Map
ME	MaineHealth Cancer Care Center of York County	Sanford04073	NCT07466316	Map
ME	Maine Children's Cancer Program	Scarborough04074	NCT07466316	Map
ME	MaineHealth Maine Medical Center- Scarborough	Scarborough04074	NCT07466316	Map
MD	Sinai Hospital of Baltimore	Baltimore21215	NCT07466316	Map
MA	Dana Farber Cancer Institute	Boston02215-5418	NCT06435429	Map
MA	Dana-Farber Cancer Institute	Boston02215	NCT07466316	Map
MA	UMass Memorial Medical Center - University Campus	Worcester01655	NCT07466316	Map
MI	University of Michigan Rogel Cancer Center	Ann Arbor48109	NCT07007559	Map
MI	Bronson Battle Creek	Battle Creek49017	NCT07466316	Map
MI	Corewell Health Grand Rapids Hospitals - Butterworth Hospital	Grand Rapids49503	NCT07466316	Map
MI	Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital	Grand Rapids49503	NCT07466316	Map
MI	Trinity Health Grand Rapids Hospital	Grand Rapids49503	NCT07466316	Map
MI	Beacon Kalamazoo	Kalamazoo49048	NCT07466316	Map
MI	Bronson Methodist Hospital	Kalamazoo49007	NCT07466316	Map
MI	West Michigan Cancer Center	Kalamazoo49007	NCT07466316	Map
MI	Trinity Health Muskegon Hospital	Muskegon49444	NCT07466316	Map
MI	Corewell Health Lakeland Hospitals - Niles Hospital	Niles49120	NCT07466316	Map
MI	Corewell Health Reed City Hospital	Reed City49677	NCT07466316	Map
MI	Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center	Saint Joseph49085	NCT07466316	Map
MI	Corewell Health Lakeland Hospitals - Saint Joseph Hospital	Saint Joseph49085	NCT07466316	Map
MI	Munson Medical Center	Traverse City49684	NCT07466316	Map
MI	University of Michigan Health - West	Wyoming49519	NCT07466316	Map
MN	Minnesota Oncology Hematology	Coon Rapids55433	NCT06435429	Map
MN	Mayo Clinic - PPDS	Rochester55905	NCT06435429	Map
MN	HealthPartners Frauenshuh Cancer Center	Saint Louis Park55426	NCT07007559	Map
MS	University of Mississippi Medical Center	Jackson39216	NCT07466316	Map
MO	Children's Mercy Hospital	Kansas City64108	NCT05999994	Map
MO	Children's Mercy Hospitals and Clinics	Kansas City64108	NCT07466316	Map
MO	Saint Luke's Cancer Institute	Kansas City64111	NCT06435429	Map
MO	Mercy Hospital Saint Louis	St Louis63141	NCT07466316	Map
MO	Washington University School of Medicine- Siteman Cancer Center	St Louis63108	NCT07007559	Map
MT	St. Vincent Regional Hospital - Cancer Centers of Montana	Billings59102	NCT07007559	Map
NE	Children's Hospital and Medical Center of Omaha	Omaha68114	NCT07466316	Map
NE	Oncology Hematology West, Pc Dba Nebraska Cancer Specialists	Omaha68130	NCT07007559	Map
NE	University of Nebraska Medical Center	Omaha68198	NCT07466316	Map
NV	Renown Regional Medical Center	Reno89502	NCT07466316	Map
NJ	Memorial Sloan Kettering Basking Ridge	Basking Ridge07920	NCT03618550	Map
NJ	Memorial Sloan Kettering Basking Ridge (All Protocol Activities)	Basking Ridge07920	NCT06377566	Map
NJ	Hackensack Meridian Health	Hackensack07601	NCT06435429	Map
NJ	Memorial Sloan Kettering Monmouth	Middletown07748	NCT03618550	Map
NJ	Memorial Sloan Kettering Monmouth (All Protocol Activities)	Middletown07748	NCT06377566	Map
NJ	Memorial Sloan Kettering Bergen	Montvale07645	NCT03618550	Map
NJ	Memorial Sloan Kettering Bergen (All Protocol Activities)	Montvale07645	NCT06377566	Map
NJ	Rutgers Cancer Institute of New Jersey	New Brunswick08901	NCT06435429	Map
NY	Albany Medical Center	Albany12208	NCT07466316	Map
NY	Memorial Sloan Kettering Cancer Center @ Commack	Commack11725	NCT03618550	Map
NY	Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities)	Commack11725	NCT06377566	Map
NY	Memorial Sloan Kettering Westchester	Harrison10604	NCT03618550	Map
NY	Memorial Sloan Kettering Westchester (All Protocol Activities)	Harrison10604	NCT06377566	Map
NY	Memorial Sloan Kettering	Long Island City11101	NCT06435429	Map
NY	Columbia University Medical Center 161 Fort Washington	New York10032-3729	NCT06435429	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT05999994	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT03618550	Map
NY	Memorial Sloan Kettering Cancer Center	New York10022	NCT07007559	Map
NY	Memorial Sloan Kettering Cancer Center (All Protocol Activities)	New York10065	NCT06377566	Map
NY	Perlmutter Cancer Center 160 E 34th St	New York10016-4744	NCT06435429	Map
NY	The Mount Sinai Hospital	New York10029	NCT06435429	Map
NY	University of Rochester	Rochester14642	NCT07466316	Map
NY	Montefiore Medical Center - Moses Campus	The Bronx10467	NCT07466316	Map
NY	Memorial Sloan Kettering Nassau	Uniondale11553	NCT03618550	Map
NY	Memorial Sloan Kettering Nassau (All Protocol Activities)	Uniondale11553	NCT06377566	Map
NC	Messino Cancer Center	Asheville28806	NCT06435429	Map
NC	Mission Hospital	Asheville28801	NCT07466316	Map
NC	Duke Cancer Institute	Durham27710-2000	NCT06435429	Map
NC	UNC Central Investigational Drug Services	Morrisville27560	NCT06435429	Map
OH	Children's Hospital Medical Center of Akron	Akron44308	NCT07466316	Map
OH	Gabrail Cancer Center	Canton44718	NCT07007559	Map
OH	Oncology Hematology Care (OHC)	Cincinnati45226	NCT06435429	Map
OH	Cleveland Clinic	Cleveland44106	NCT06875128	Map
OH	Nationwide Children's Hosp	Columbus43205-2664	NCT05999994	Map
OH	Ohio State University, Stefanie Spielman Comprehensive Breast Center	Columbus43212	NCT06875128	Map
OH	ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital	Toledo43606	NCT07466316	Map
OR	Legacy Emanuel Children's Hospital	Portland97227	NCT07466316	Map
OR	Oregon Health and Science University	Portland97239	NCT07007559	Map
PA	Lehigh Valley Hospital-Cedar Crest	Allentown18103	NCT07466316	Map
PA	Abramson Cancer Center of The University of Pennsylvania	Philadelphia19104	NCT06435429	Map
PA	Children's Hospital of Philadelphia	Philadelphia19104	NCT07466316	Map
PA	Fox Chase Cancer Center	Philadelphia19111	NCT06435429	Map
PA	Saint Christopher's Hospital for Children	Philadelphia19134	NCT07466316	Map
PA	Children's Hospital of Pittsburgh of UPMC	Pittsburgh15224	NCT07466316	Map
PA	UPMC Children's Hospital of Pittsburgh	Pittsburgh15224	NCT05999994	Map
RI	Lifespan Cancer Institute	Providence02906	NCT05999994	Map
RI	Rhode Island Hospital	Providence02903	NCT06435429	Map
RI	Rhode Island Hospital	Providence02903	NCT07466316	Map
TN	East Tennessee Childrens Hospital	Knoxville37916	NCT07466316	Map
TN	St. Jude Children's Research Hospital	Memphis38105	NCT06023641	Map
TN	Sarah Cannon Research Institute	Nashville37203	NCT06435429	Map
TN	The Children's Hospital at TriStar Centennial	Nashville37203	NCT07466316	Map
TX	Dell Children's Medical Center of Central Texas	Austin78723	NCT07466316	Map
TX	Driscoll Children's Hospital	Corpus Christi78411	NCT07466316	Map
TX	University of Texas Southwestern Medical Center	Dallas75390	NCT07007559	Map
TX	University of Texas Southwestern Medical Center at Dallas	Dallas75390-9063	NCT05999994	Map
TX	UT Southwestern Medical Center	Dallas75325	NCT06875128	Map
TX	UT Southwestern/Simmons Cancer Center-Dallas	Dallas75390	NCT07466316	Map
TX	Texas Oncology - Fort Worth	Fort Worth76104	NCT06435429	Map
TX	Houston Methodist Cancer Center	Houston77030	NCT07007559	Map
TX	The University of Texas M.D. Anderson Cancer Center	Houston77030	NCT07007559	Map
TX	U.T. MD Anderson Cancer Center, Investigational Pharmacy Services	Houston77030	NCT06435429	Map
TX	University of Texas MD Anderson Cancer Center	Houston77030	NCT05999994	Map
TX	Maryland Oncology Hematology Healing Way - USOR	Irving75063	NCT06435429	Map
TX	Medical Oncology Hematology Consultants	Irving75063	NCT06435429	Map
TX	Nexus Health	Irving75063	NCT06435429	Map
TX	Sansum Clinic 540 W - USOR	Irving75063	NCT06435429	Map
TX	Texas Oncology Gulf Coast	Irving75063	NCT06435429	Map
TX	Texas Oncology West	Irving75063	NCT06435429	Map
TX	Methodist Children's Hospital of South Texas	San Antonio78229	NCT07466316	Map
TX	University of Texas Health Science Center at San Antonio	San Antonio78229	NCT07466316	Map
UT	Primary Children's Hospital	Salt Lake City84113	NCT07466316	Map
VA	University of Virginia Cancer Center	Charlottesville22908	NCT07466316	Map
VA	Virginia Cancer Specialists	Fairfax22031	NCT06435429	Map
VA	Virginia Cancer Specialists	Fairfax22031	NCT07007559	Map
VA	Inova Fairfax Hospital	Falls Church22042	NCT07466316	Map
VA	Children's Hospital of The King's Daughters	Norfolk23507	NCT07466316	Map
VA	Virginia Oncology Associates, Sentara Health	Norfolk23502	NCT06435429	Map
VA	Blue Ridge Cancer Care	Roanoke24014	NCT06435429	Map
WA	Fred Hutchinson Cancer Center	Seattle98109	NCT06435429	Map
WA	Fred Hutchinson Cancer Center	Seattle98109	NCT07007559	Map
WA	Seattle Children's Hospital	Seattle98105	NCT07466316	Map
WA	Seattle Children's Hospital Research Foundation	Seattle98105	NCT05999994	Map
WA	Mary Bridge Children's Hospital and Health Center	Tacoma98405	NCT07466316	Map
WI	University of Wisconsin Carbone Cancer Center - Eastpark Medical Center	Madison53718	NCT07466316	Map
WI	University of Wisconsin Carbone Cancer Center - University Hospital	Madison53792	NCT07466316	Map
WI	Children's Hospital of Wisconsin	Milwaukee53226	NCT07466316	Map
WI	Froedtert and The Medical College of Wisconsin	Milwaukee53226	NCT06435429	Map

Vinorelbine clinical trials at a glance: phase × recruitment status

Phase	recruiting	active not recruiting	completed	terminated	withdrawn	not yet recruiting	unknown	no longer available	Total
Early P1			1		1				2
P1		1	27	5	1		6		40
P1/P2	3		14	6			1		24
P2	11	5	117	28	5	5	54		225
P2/P3			1	3			2		6
P3	14	13	43	9	5	2	17		103
P4			5				2		7
N/A	2	1	6	2			7	1	19

Recruiting Vinorelbine clinical trials (37)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT ID	Title	Phase	Indication	Enrollment	Started
NCT06023641	Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease	P2	Rhabdomyosarcoma	135	Mar 2024
NCT07021989	ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma	P2	Hodgkin Lymphoma, Adult	38	Aug 2026
NCT07001618	IMMUNOLIFE2Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer	P2	NSCLC (Advanced Non-small Cell Lung Cancer)	162	Nov 2025
NCT07466316	IR RMSA Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)	P3	Rhabdomyosarcoma	342	Jul 2026
NCT06255392	Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer	P3	Fludzoparib" and Anti-angiogenic	200	Jun 2024
NCT02813135	ESMARTEuropean Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors	P1/P2	Pediatric Cancer	472	Aug 2016
NCT06435429	A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer	P3	Metastatic HER2-positive Breast Cancer	550	Aug 2024
NCT04625907	FaR-RMSFaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma	P1/P2	Rhabdomyosarcoma	1,672	Sep 2020
NCT07406542	A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer	P3	Recurrent or Metastatic Breast Cancer	400	Apr 2026
NCT07533123	A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care	P3	Triple Negative Breast Cancer	364	Mar 2026
NCT06692491	SPRINGStudy of Precision Treatment for Rare Tumours in China Guided by PDO and NGS	P2	Rare Tumour	200	Jan 2025
NCT06875128	DELUMAEvaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease	P2	Metastatic Breast Cancer in the Liver	90	Jan 2026
NCT05487391	A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.	P3	Carcinoma, Non-Small-Cell Lung	632	Dec 2022
NCT06079983	JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects	P3	Breast Cancer	400	Dec 2023
NCT07007559	ASPEN-09-03ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer	P2	Breast Cancer, Metastatic	120	Dec 2025
NCT07137884	ALTER-02Anlotinib Hydrochloride Capsules in Maintenance Treatment for Intermediate-High Risk Rhabdomyosarcoma in Children	P2	Rhabdomyosarcoma Recurrent	150	Oct 2025
NCT07420439	Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease	P2	Non Small Cell Lung Cancer Metastatic	108	Sep 2026
NCT06383767	A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer	P3	Metastatic Breast Cancer	378	Jul 2024
NCT05901935	DP303c in Patients With HER2-positive Advanced Breast Cancer	P3	HER2-positive Advanced Breast Cancer	420	Jul 2023
NCT06908993	COMETTepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated	P3	Advanced Non Small Cell Lung Cancer	133	Dec 2025
NCT07461454	YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer	P3	Locally Advanced or Metastatic Breast Cancer	376	Mar 2026
NCT06102824	ORIENTAOrganoid-based Functional Precision Therapy for Advanced Breast Cancer	P2	HER2-negative Breast Cancer	252	Oct 2024
NCT07088263	Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer	P3	Breast Neoplasms	192	Sep 2025
NCT06268652	Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer	P3	Breast Cancer	302	Jan 2024
NCT06908304	A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC	P3	Carcinoma, Non-Small -Cell Lung	300	Dec 2025
NCT06081959	Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer	P3	Metastatic Breast Cancer	376	Oct 2023
NCT05856383	HER2-VIPEfficacy and Safety of Inetetamab Combined With Pyrotinib and Vinorelbine in ABC	—	HER2-positive Advanced Breast Cancer	100	Mar 2022
NCT06202261	A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer	P1/P2	Metastatic Breast Cancer	154	Apr 2023
NCT03618550	Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma	P2	Hodgkin Lymphoma	257	Aug 2018
NCT06489808	Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL	P2	Relapsed/Refractory Large B-Cell Lymphoma	89	May 2024
NCT05999994	CAMPFIREA Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer	P2	Neoplasms	105	Jan 2020
NCT06377566	A Study of BV-AVD in People With Bulky Hodgkin Lymphoma	P2	Hodgkin Lymphoma	71	Apr 2024
NCT06690840	AZALEAAtezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients	P2	Triple Negative Breast Cancer	45	Mar 2025
NCT06229067	Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer	P2	Breast Cancer	182	Jan 2024
NCT06576635	LUNG-05LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic Patients	N/A	NSCLC	29	Dec 2024
NCT06653972	EASOVCWDITHABCEfficacy and Safety of a Two-week Dosing Regimen of Vinorelbine Combined with Liposomal Doxorubicin in the Treatment of HER2-negative Advanced Breast Cancer	P2	Her2-negative Metastatic Breast Cancer	30	Nov 2024
NCT06143553	Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer	P3	Metastatic Breast Cancer (MBC)	168	Sep 2023

Vinorelbine clinical trials by indication

Breast Cancer (81)

NCT	Acronym	Phase	Status	Title
NCT06079983	—	P3	recruiting	JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
NCT06268652	—	P3	recruiting	Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer
NCT04759248	ATREZZO	P2	active not recruiting	Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer
NCT03414658	—	P2	active not recruiting	The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer
NCT06229067	—	P2	not yet recruiting	Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer
NCT05104866	ICC	P3	active not recruiting	A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
NCT04922008	—	P2	unknown	Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS-C/D)
NCT04296162	ORCHID	P2	completed	Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID)
+ 73 more, see All trials below.

Lung Cancer (35)

NCT	Acronym	Phase	Status	Title
NCT02644252	Toco-Pulm	P3	terminated	Tocotrienol as a Nutritional Supplement in Patients With Advanced Lung Cancer
NCT02709720	NORA	P2	completed	Study of Vinorelbine and Cisplatin as Induction Therapy With Radiotherapy in Patients With Unresectable NSCLC
NCT01443078	NEOSCAN	P2	completed	Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)
NCT00863512	—	P3	terminated	Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer
NCT00675597	—	N/A	completed	Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer
NCT00540982	—	P1/P2	completed	Vinorelbine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Treatment and Liver Dysfunction
NCT00287963	—	P1	completed	Topotecan and Vinorelbine in Treating Patients With Recurrent Lung Cancer
NCT00253591	—	P2/P3	completed	Radiation Therapy With or Without Vinorelbine and Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
+ 27 more, see All trials below.

Metastatic Breast Cancer (30)

NCT	Acronym	Phase	Status	Title
NCT06383767	—	P3	recruiting	A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer
NCT06081959	—	P3	recruiting	Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
NCT06202261	—	P1/P2	recruiting	A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer
NCT04639986	IMMU-132	P3	active not recruiting	Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)
NCT02344472	—	P3	unknown	Detect V / CHEVENDO (Chemo vs. Endo)
NCT04143906	—	P2	unknown	Vinorelbine/Carboplatin Versus Gemcitabine/Carboplatin in Metastatic Breast Cancer
NCT03355157	PADMA	P4	completed	A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).
NCT04963595	—	P2	unknown	Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer
+ 22 more, see All trials below.

Non Small Cell Lung Cancer (16)

NCT	Acronym	Phase	Status	Title
NCT02998528	CheckMate 816	P3	completed	A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)
NCT02117024	HS-110	P2	terminated	A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer
NCT00755170	—	P2	completed	Metronomic Vinorelbine and Bevacizumab in Patients With Non Small Cell Lung Cancer
NCT01029678	RACCOSA	P2	completed	Concomitant Radio-chemotherapy in the Elderly
NCT01784549	CONTEST	P2	unknown	Customized Neoadjuvant Versus Standard Chemotherapy in NSCL Patients With Resectable Stage IIIA (N2)Disease
NCT02319577	—	P2	unknown	GEfitinib Plus viNOrelbine in Advanced EGFR Mutated NSCLC. GENOA Trial
NCT02497118	—	P4	completed	Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLC
NCT00686959	PROCLAIM	P3	completed	Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
+ 8 more, see All trials below.

Carcinoma, Non-Small-Cell Lung (11)

NCT	Acronym	Phase	Status	Title
NCT03456076	—	P3	active not recruiting	A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer
NCT05487391	—	P3	recruiting	A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.
NCT05603013	—	P2	unknown	Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)
NCT03345810	DURATION	P2	completed	Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)
NCT02919462	HighTySy	P2	terminated	Open-label, Multicenter, Randomized Phase II Trial of Treatment With Cisplatin and Pemetrexed or Cisplatin and Oral Vinorelbine in Chemotherapy Naïve Patients Affected by Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer With High Thymidylate Synthase Expression
NCT00842712	CERTO	P2	completed	Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC)
NCT01684111	VENUS-1	P1	completed	An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Vinorelbine in Elderly Patients With Advanced Non Small Lung Cell Cancer - Stage IV (VENUS-1)
NCT01683682	VENUS-2	P1	completed	An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Carboplatin and Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer - Stage IV (VENUS-2)
+ 3 more, see All trials below.

Non-Small Cell Lung Cancer (10)

NCT	Acronym	Phase	Status	Title
NCT02486718	MPDL3280A	P3	active not recruiting	Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
NCT03770299	CheckMate 9TN	P2	withdrawn	An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease
NCT03191786	IPSOS	P3	completed	A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy
NCT00499109	—	P3	completed	Phase III of RRM1 & ERCC1 Directed Customized Chemotherapy for the Treatment of Patients With NSCLC
NCT00870532	—	P1	completed	Study of Combination of Metronomic Oral Vinorelbine and Sorafenib in Patients With Advanced Non-small Cell Lung Cancer
NCT00702182	—	P1	completed	Study of Oral Vinorelbine and Erlotinib in Non-Small Cell Lung Cancer
NCT01196078	—	P4	completed	A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer
NCT00678964	TIE	P2	unknown	Erlotinib Versus Carboplatin/Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
+ 2 more, see All trials below.

Breast Neoplasms (9)

NCT	Acronym	Phase	Status	Title
NCT07088263	—	P3	recruiting	Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer
NCT03242616	—	P2	completed	PemVin vs Vin in Previously Treated Metastatic Breast Cancer
NCT05764941	—	N/A	unknown	Inetetamab Combined With Pyrotinib and Vinorelbine as First-line to Third-line Treatment for HER2-positive Metastatic Breast Cancer
NCT02229149	—	P2	terminated	Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer
NCT01125566	—	P3	completed	LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment
NCT01271725	—	P2	completed	LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures
NCT01325428	BIBW2992	P2	completed	Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer
NCT01441596	HER2	P2	completed	Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases
+ 1 more, see All trials below.

Lymphoma (8)

NCT	Acronym	Phase	Status	Title
NCT00574496	—	P2	completed	Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma
NCT00920153	—	P3	terminated	Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma
NCT00392691	—	P1	completed	Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment
NCT00881387	—	P2	withdrawn	Rituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to Treatment
NCT00006760	—	P2	completed	Combination Chemotherapy in Treating Children With Refractory or Relapsed Hodgkin's Lymphoma
NCT00006029	—	P1/P2	completed	Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
NCT00003963	—	P2	completed	Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell Transplantation
NCT00070304	—	P2	completed	Gemcitabine and Vinorelbine in Treating Young Patients With Recurrent or Refractory Hodgkin's Lymphoma

Non-small Cell Lung Cancer (7)

NCT	Acronym	Phase	Status	Title
NCT06564844	TROPION-Lung12	P3	active not recruiting	A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features
NCT03801304	VinMetAtezo	P2	completed	Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung Cancer
NCT01405079	ADJUVANT	P3	unknown	Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation
NCT01749072	—	P2	unknown	Vinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients
NCT00434668	TOLEDO	P2	completed	Evaluation of Tolerability of Adjuvant Cisplatin/Docetaxel in Completely Resected Stage IB/II Non-Small Cell Lung Cancer
NCT01687439	NSCLC	P2	completed	Effect of Endostar Combined With Chemotherapy and Radiotherapy on Blood Vessels and Microenvironment of Tumor for Non-small Cell Lung Cancer (NSCLC)
NCT00165334	—	P2	completed	Cetuximab and Vinorelbine in Elderly Subjects With Lung Cancer

Prostate Cancer (7)

NCT	Acronym	Phase	Status	Title
NCT00003622	—	P2	withdrawn	Vinorelbine Plus Paclitaxel in Treating Patients With Metastatic Prostate Cancer That Is Refractory to Hormone Therapy
NCT00627354	—	P2	completed	Mitoxantrone, Etoposide, and Vinorelbine As Second-Line Therapy in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
NCT00151086	—	P1/P2	completed	Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer
NCT00005847	—	P2	completed	Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
NCT00003400	—	P2	completed	Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer
NCT00003259	—	P2	completed	Vinorelbine in Treating Patients With Metastatic Prostate Cancer
NCT00006114	—	P2	unknown	Combination Chemotherapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Triple Negative Breast Cancer (6)

NCT	Acronym	Phase	Status	Title
NCT07533123	—	P3	recruiting	A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care
NCT06519370	—	P3	active not recruiting	FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer
NCT06690840	AZALEA	P2	recruiting	Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients
NCT04745975	—	P2	unknown	Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer
NCT05134194	—	P3	terminated	A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer
NCT03358004	VICTOR3	P2	terminated	the Role of Two Different Metronomic Chemotherapy Regimens in Locally Advanced or Metastatic Triple Negative Breast Cancer Patients (TNBC) as Maintenance Therapy After First Line Treatment

NSCLC (6)

NCT	Acronym	Phase	Status	Title
NCT06576635	LUNG-05	N/A	recruiting	LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic Patients
NCT02795884	—	P3	withdrawn	Adjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR Mutation
NCT03656393	RCTACSCNSCLC	P3	unknown	To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung Adenocarcinoma
NCT02940990	—	P2	unknown	SBRT in Multi-metastatic NSCLC Patients Which Are Pan-negative for Driver Mutations
NCT00298415	NSCLC	P3	completed	Chemotherapy of Elderly Patients With Non-Small-Cell Lung Cancer (NSCLC)
NCT00683514	—	P3	completed	Oral Chemotherapy And Platinum With Radiotherapy Followed Or Not By Consolidation With The Same Chemotherapy In Locally Advanced Non Small Cell Lung Cancer

Rhabdomyosarcoma (5)

NCT	Acronym	Phase	Status	Title
NCT06023641	—	P2	recruiting	Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
NCT07466316	IR RMS	P3	recruiting	A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
NCT04625907	FaR-RMS	P1/P2	recruiting	FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
NCT04299113	—	P1	active not recruiting	Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma
NCT04388839	—	P2	active not recruiting	Evolutionary Therapy for Rhabdomyosarcoma

Advanced Breast Cancer (4)

NCT	Acronym	Phase	Status	Title
NCT06500494	VINOREAL	N/A	active not recruiting	To Describe How Well Vinorelbine Given Orally Works in Patients With a Breast Cancer After 2 Years of Treatment
NCT05063786	ALPHABET	P3	active not recruiting	Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)
NCT04304352	VEX	P2	unknown	Metronomic Oral Chemotherapy With Cyclophosphamide, Capecitabine and Vinorelbine in Metastatic Breast Cancer Patients
NCT03811418	ATTILA	P3	withdrawn	A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer

Cervical Cancer (3)

NCT	Acronym	Phase	Status	Title
NCT06459180	MK-2870	P3	active not recruiting	A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
NCT04697628	innovaTV 301	P3	completed	Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
NCT00002813	—	P2	completed	Combination Chemotherapy in Treating Patients With Recurrent or Refractory Cervical Cancer

Triple-negative Breast Cancer (3)

NCT	Acronym	Phase	Status	Title
NCT06355037	—	P2	unknown	Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer
NCT06355024	—	P2	completed	Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer
NCT03932526	—	P2	unknown	Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer

HER2-positive Advanced Breast Cancer (3)

NCT	Acronym	Phase	Status	Title
NCT05901935	—	P3	not yet recruiting	DP303c in Patients With HER2-positive Advanced Breast Cancer
NCT05856383	HER2-VIP	N/A	recruiting	Efficacy and Safety of Inetetamab Combined With Pyrotinib and Vinorelbine in ABC
NCT04903652	—	P2	completed	Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast Cancer

Advanced Non-Small Cell Lung Cancer (3)

NCT	Acronym	Phase	Status	Title
NCT04922658	—	P2	active not recruiting	Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer
NCT00737867	—	P3	completed	Vinorelbine/Gemcitabine Versus Vinorelbine/Carboplatin in Advanced Non-small Cell Lung Cancer
NCT00345059	DISTAL-2	P3	terminated	The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer

Neoplasms (3)

NCT	Acronym	Phase	Status	Title
NCT05999994	CAMPFIRE	P2	recruiting	A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
NCT01214616	—	P1	completed	BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid Tumours
NCT00906698	—	P1	completed	Afatinib and Vinorelbine in Tumours Known to Overexpress EGFR and/or HER2

Non-small Cell Lung Cancer Stage IIIA (3)

NCT	Acronym	Phase	Status	Title
NCT02974426	N2	P3	terminated	To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer
NCT02977169	N2	P2	unknown	To Evaluate the Role of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer
NCT01410214	—	P2	unknown	Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations

Mesothelioma (3)

NCT	Acronym	Phase	Status	Title
NCT02139904	VIM	P2	completed	Vinorelbine in Mesothelioma
NCT02610140	MPM	P2	completed	Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)
NCT00597116	—	P2	terminated	An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma

Cancer (3)

NCT	Acronym	Phase	Status	Title
NCT02777788	TCM	P2/P3	unknown	Curative Study of Chinese Traditional Medicine to Treat Lung Cancer
NCT01013740	VITAL	P2	completed	Lapatinib in Combination With Vinorelbine
NCT01128543	—	P2	completed	Lapatinib in Combination With Vinorelbine

Hodgkin Disease (3)

NCT	Acronym	Phase	Status	Title
NCT00388349	—	P2	completed	Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease
NCT00636311	—	P2	completed	A Phase II Study of IGEV +/- Bortezomib Before Hign Dose Consolidation in Relapsed/Refractory Hodgkin's Lymphoma
NCT00225173	—	P2	terminated	Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease

Leukemia (3)

NCT	Acronym	Phase	Status	Title
NCT00462787	—	P1	completed	Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Leukemia
NCT00477035	CIK	P1	completed	Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies
NCT00004105	—	P1/P2	completed	Combination Chemotherapy in Treating Patients With Advanced Cancer

Unspecified Adult Solid Tumor, Protocol Specific (3)

NCT	Acronym	Phase	Status	Title
NCT00389922	—	P1	completed	Lapatinib and Vinorelbine in Treating Patients With Advanced Solid Tumors
NCT00006372	—	P1	completed	Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
NCT00006088	—	P1	unknown	Vinorelbine in Treating Patients With Metastatic or Advanced Solid Tumors

Malignant Mesothelioma (3)

NCT	Acronym	Phase	Status	Title
NCT00354393	—	P2	completed	Combination Chemotherapy With or Without Surgery & Chemoradiotherapy in Patients With Malignant Pleural Mesothelioma
NCT00075699	—	P3	completed	Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma
NCT00030459	—	P2	unknown	Palliative Therapy With or Without Chemotherapy in Treating Patients With Malignant Mesothelioma

Advanced Non Small Cell Lung Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT06908993	COMET	P3	recruiting	Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated
NCT03652857	—	P2	completed	Apatinib Combined With Vinorelbine for Non-driver Gene Mutation Non-small Cell Lung Cancer

Her2-negative Metastatic Breast Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT06653972	EASOVCWDITHABC	P2	not yet recruiting	Efficacy and Safety of a Two-week Dosing Regimen of Vinorelbine Combined with Liposomal Doxorubicin in the Treatment of HER2-negative Advanced Breast Cancer
NCT01520103	VicTORia	P2	completed	Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer

HER2-negative Breast Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT06102824	ORIENTA	P2	recruiting	Organoid-based Functional Precision Therapy for Advanced Breast Cancer
NCT04848454	—	P2	unknown	Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy

Hodgkin Lymphoma (2)

NCT	Acronym	Phase	Status	Title
NCT03618550	—	P2	recruiting	Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
NCT06377566	—	P2	recruiting	A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Non-small Cell Lung Cancer Stage III (2)

NCT	Acronym	Phase	Status	Title
NCT04765709	BRIDGE	P2	terminated	Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC
NCT01683175	—	P2	unknown	Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation

Alveolar Rhabdomyosarcoma (2)

NCT	Acronym	Phase	Status	Title
NCT04994132	—	P3	active not recruiting	A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma
NCT02567435	—	P3	active not recruiting	Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

Advanced Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT04943627	BRAVA	P3	withdrawn	Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)
NCT02331251	—	P1/P2	terminated	Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)

Breast Cancer Metastatic (2)

NCT	Acronym	Phase	Status	Title
NCT04262804	—	P2	unknown	A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC
NCT03321981	—	P2	completed	MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

HER2 Positive Breast Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT03947242	—	N/A	unknown	Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer.
NCT02362958	—	P2	completed	A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer

Multiple Myeloma (2)

NCT	Acronym	Phase	Status	Title
NCT03442673	MOCCCA	P2	completed	Chemotherapy and G-CSF for Mobilization
NCT02791373	ViGeM	P2	completed	Vinorelbine and Gemcitabine in Myeloma

Ovarian Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT03188159	—	P2	unknown	Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer
NCT01196559	—	P2	completed	Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Ovarian Cancer

Pediatric Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT02813135	ESMART	P1/P2	recruiting	European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
NCT02897986	PROVIN	P1	unknown	Study of a Propranolol (HEMANGIOL®) and Oral Metronomic Vinorelbine (NAVELBINE®) Combination for Children and Teenagers With Refractory/Relapsing Solid Tumors

Anaplastic Large Cell Lymphoma (2)

NCT	Acronym	Phase	Status	Title
NCT03443128	—	P2	completed	Vinorelbine for Recurrent ALCL-2017
NCT03397953	—	P2	completed	Vinorelbine for Recurrent ACLC

Non-Small-Cell Lung Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT02619929	StepUp	N/A	completed	Initial Oral Vinorelbine Dosing Schedules in Clinical Routine in Germany and Austria
NCT00705549	—	P2	terminated	Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer

Non Small Cell Lung Cancer (NSCLC) (2)

NCT	Acronym	Phase	Status	Title
NCT02555007	NVB Metro	P1	completed	Metronomic Chemotherapy Based on Adaptative Bio-mathematical Model of Oral Vinorelbine in Patients With NSCLC or MPM
NCT00148798	FLEX	P3	completed	Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX)

Neoplasms, Breast (2)

NCT	Acronym	Phase	Status	Title
NCT01137994	—	P2	withdrawn	A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
NCT00709618	—	P2	terminated	Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects

Hodgkin's Lymphoma (2)

NCT	Acronym	Phase	Status	Title
NCT01884441	—	P2	unknown	Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients
NCT01884428	—	P1	unknown	Study of Combination of PIGEV Before Autologous Stem Cell Transplant in Patients With Hodgkin's Lymphoma

Estrogen Receptor-negative Breast Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT01104259	—	P1	completed	Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer
NCT00194779	—	P2	completed	Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery

Adult Lymphocyte Depletion Hodgkin Lymphoma (2)

NCT	Acronym	Phase	Status	Title
NCT00381940	—	P2	completed	Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy
NCT00337194	—	P2	completed	SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Non-Hodgkin's Lymphoma (2)

NCT	Acronym	Phase	Status	Title
NCT00163761	—	P2	completed	Efficacy Study of Outpatient Therapy for Lymphoma
NCT00163748	—	P2	completed	Efficacy and Treatment Related Toxicity Study of a New Regimen for Lymphoma

Breast Neoplasm (2)

NCT	Acronym	Phase	Status	Title
NCT00194727	—	P2	completed	Weekly Vinorelbine and Oral Capecitabine as Treatment for Stage IV Breast Cancer
NCT00194740	—	P2	completed	Taxotere Plus Weekly Navelbine and G-CSF: A Study in Stage IV Breast Cancer

Non Small Cell Lung Cancer Metastatic (1)

NCT	Acronym	Phase	Status	Title
NCT07420439	—	P2	not yet recruiting	Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

Hodgkin Lymphoma, Adult (1)

NCT	Acronym	Phase	Status	Title
NCT07021989	—	P2	recruiting	ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

Recurrent or Metastatic Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT07406542	—	P3	not yet recruiting	A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer

Locally Advanced or Metastatic Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT07461454	—	P3	recruiting	YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

Metastatic Breast Cancer in the Liver (1)

NCT	Acronym	Phase	Status	Title
NCT06875128	DELUMA	P2	recruiting	Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease

Breast Cancer, Metastatic (1)

NCT	Acronym	Phase	Status	Title
NCT07007559	ASPEN-09-03	P2	recruiting	ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

Carcinoma, Non-Small -Cell Lung (1)

NCT	Acronym	Phase	Status	Title
NCT06908304	—	P3	recruiting	A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

NSCLC (Advanced Non-small Cell Lung Cancer) (1)

NCT	Acronym	Phase	Status	Title
NCT07001618	IMMUNOLIFE2	P2	recruiting	Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer

Rhabdomyosarcoma Recurrent (1)

NCT	Acronym	Phase	Status	Title
NCT07137884	ALTER-02	P2	not yet recruiting	Anlotinib Hydrochloride Capsules in Maintenance Treatment for Intermediate-High Risk Rhabdomyosarcoma in Children

Rare Tumour (1)

NCT	Acronym	Phase	Status	Title
NCT06692491	SPRING	P2	not yet recruiting	Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS

Resectable Lung Non-Small Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT06632327	—	P3	active not recruiting	Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

Metastatic HER2-positive Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06435429	—	P3	recruiting	A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

HER2-negative Metastatic Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06533722	—	P2	completed	Adaptive Therapy for Post-Second-Line Advanced Breast Cancer

Triple-Negative Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06382142	—	P3	active not recruiting	A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)

Fludzoparib" and Anti-angiogenic (1)

NCT	Acronym	Phase	Status	Title
NCT06255392	—	P3	recruiting	Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

Relapsed/Refractory Large B-Cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT06489808	—	P2	recruiting	Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL

Classical Hodgkin Lymphoma Relapsed (1)

NCT	Acronym	Phase	Status	Title
NCT07450508	BEGEV	P3	completed	Study of Bendamustine, Gemcitabine and Vinorelbine Regimen in Relapsed/Refractory Classical Hodgkin Lymphoma

HR+HER2- Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06343948	—	P3	active not recruiting	A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)

EGFR/ ALK-negative Advanced NSCLC (1)

NCT	Acronym	Phase	Status	Title
NCT06260553	—	P2	unknown	Metronomic Oral Vinorelbine Combination With Tislelizumab in EGFR/ALK-negative Advanced NSCLC

Breast Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT06137651	—	P1	withdrawn	Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal Metastasis

Metastatic Breast Cancer (MBC) (1)

NCT	Acronym	Phase	Status	Title
NCT06143553	—	P3	recruiting	Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer

Recurrent Classic Hodgkin Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT05711628	—	P3	withdrawn	A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma

Vinorelbine (1)

NCT	Acronym	Phase	Status	Title
NCT06540950	—	P2	active not recruiting	Efficacy and Safety of Concurrent Chemoradiotherapy With Oral Vinorelbine in Patients With Non-small Cell Lung Cancer

HER2-positive Metastatic Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT05583110	TrasTUCAN	P2	terminated	Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer

Advanced Breast Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT05238831	ACT	Early P1	withdrawn	SMMART Adaptive Clinical Treatment (ACT) Trial

EGFR (1)

NCT	Acronym	Phase	Status	Title
NCT05663177	—	N/A	unknown	Almonertinib Plus Metronomic Oral Vinorelbine

Classical Hodgkin Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT04624984	—	P2	unknown	PD-1 Inhibitor or PD-1 Inhibitor Plus GVD for Relapsed/Refractory CHL

Desmoplastic Small Round Cell Tumor (1)

NCT	Acronym	Phase	Status	Title
NCT04145349	LY3009806	P1/P2	completed	CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor

Lymphoma, Large B-Cell, Diffuse (1)

NCT	Acronym	Phase	Status	Title
NCT04021992	—	P2	unknown	GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL

Lung Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT03891173	—	P2	terminated	A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma

Breast Cancer Organoids (1)

NCT	Acronym	Phase	Status	Title
NCT03925233	—	N/A	unknown	Breast Cancer Treatment Based on Organ-like Culture

Pathologic Residual Cancer Cells (1)

NCT	Acronym	Phase	Status	Title
NCT03703427	—	P2	unknown	Capecitabine Versus Vinorelbine in High Risk Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy

Advanced Solid Tumours (1)

NCT	Acronym	Phase	Status	Title
NCT03518606	MOVIE	P1/P2	completed	Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours

HER2-positive Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06107790	—	P3	completed	Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast Cancer

Locally Advanced/ Metastatic NSCLC (1)

NCT	Acronym	Phase	Status	Title
NCT04208854	VINORELBINA	N/A	unknown	Observational Study With Metronomic Oral Vinorelbine in Elderly Patients With Locally Advanced / Metastatic Non-small-cell Lung Cancer (NSCLC)

Completely Resected NSCLC With Common EGFR Mutations (1)

NCT	Acronym	Phase	Status	Title
NCT03381066	—	P3	unknown	A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations.

Colon Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03482362	EORTC1616	P2	completed	Vinorelbine in Advanced BRAF-like Colon Cancer

Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers (1)

NCT	Acronym	Phase	Status	Title
NCT03386721	—	P2	terminated	Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors

Hormone Receptor Positive Advanced Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03939871	—	P2	unknown	A Study of Fluvestrant Combined With Oral Vinorelbine in Hormone Receptor-positive Advanced Breast Cancer

Primary Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03270007	—	P4	unknown	Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy

Pleural Mesothelioma Malignant Advanced (1)

NCT	Acronym	Phase	Status	Title
NCT02991482	PROMISE-meso	P3	completed	PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma

Aggressive Non-Hodgkin Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT03161054	—	P2	completed	Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas

Advanced Triple-Negative Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT03254654	—	P2	completed	Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer

Lung Neoplasm Malignant (1)

NCT	Acronym	Phase	Status	Title
NCT02985203	—	P2	terminated	Oral Navelbine and Cisplatin Followed by Metronomic Oral Navelbine in Non-Small Cell Lung Cancer

Metastasis (1)

NCT	Acronym	Phase	Status	Title
NCT02915744	ATTAIN	P3	completed	A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine

Malignant Hydrothorax (1)

NCT	Acronym	Phase	Status	Title
NCT02579564	—	P3	unknown	Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients

HER2-expressing Cancers (1)

NCT	Acronym	Phase	Status	Title
NCT02892123	—	P1	completed	Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

Diffuse Large B-cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT02733380	—	P2	unknown	Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma

Diffuse Intrinsic Pontine Glioma (1)

NCT	Acronym	Phase	Status	Title
NCT03620032	DIPG	P2	unknown	Study of Re-irradiation at Relapse Versus RT and Multiple Elective rt Courses

Metastatic Triple Negative Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT02555657	MK-3475	P3	completed	Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)

HER2-positive Locally Advanced or Metastatic Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT02514681	PRECIOUS	P3	completed	A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer

Esophageal Squamous Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT02465736	NEOCRTEC308	P3	unknown	Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer (NEOCRTEC308)

Small Cell Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT02489903	QUADRUPLE THREAT	P2	completed	RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Non - Small Cell Lung Cancer NSCLC (1)

NCT	Acronym	Phase	Status	Title
NCT02352948	ARCTIC	P3	completed	A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

Non-small Cell Lung Cancer Stage Ⅱ (1)

NCT	Acronym	Phase	Status	Title
NCT02223611	S1VSNP	P2	unknown	Clinical Observation of S1 Capsule for Stage Ⅱ-ⅢA Non-small Cell Lung Cancer After Complete Resection

Stage Ib Lung Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT02281708	—	P3	unknown	Multicenter Randomized Controlled Trial Adjuvant Chemotherapy vs Observation in pStage Ib Lung Adenocarcinoma

Low-Grade Glioma (1)

NCT	Acronym	Phase	Status	Title
NCT02197637	OVIMA-1210	P2	completed	Phase II Trial of Oral Vinorelbine in Children With Recurrent or Progressive Unresectable Low-Grade Glioma

HER2-Negative Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT02225470	—	P3	completed	Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

Non-small Cell Lung Cancer Stage IIIB (1)

NCT	Acronym	Phase	Status	Title
NCT02176369	ONC-MANILA12	P2	completed	Maintenance Low Dose Oral Navelbine In Patients With Non Small Cell Lung Cancer - MA.NI.LA Trial

Non-small Cell Lung Cancer Metastatic (1)

NCT	Acronym	Phase	Status	Title
NCT01848613	VIVOS	P4	completed	Study of Patient Preference for Oral or Intravenous Vinorelbine in the Treatment of Advanced NSCLC

Stage IV, NSCLC (1)

NCT	Acronym	Phase	Status	Title
NCT03402048	EPIC	P3	unknown	The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial

Carcinoma Breast Stage IV (1)

NCT	Acronym	Phase	Status	Title
NCT01531764	—	P2	terminated	BIBW 2992 (Afatinib) and Vinorelbine

Non-Small Cell Lung Cancer (NSCLC) (1)

NCT	Acronym	Phase	Status	Title
NCT01454934	—	P3	completed	A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer

HER-2 Positive Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT01305941	—	P2	completed	A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases

Low-grade Glioma (1)

NCT	Acronym	Phase	Status	Title
NCT01497860	—	P2	completed	Vinorelbine for Children With Progressive or Recurrent Low-grade Gliomas

Adult Rhabdomyosarcoma (1)

NCT	Acronym	Phase	Status	Title
NCT01222715	—	P2	completed	Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma

Lung Neoplasms (1)

NCT	Acronym	Phase	Status	Title
NCT01109524	—	P2	completed	Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer

Carcinoma, Invasive Ductal, Breast (1)

NCT	Acronym	Phase	Status	Title
NCT01126138	NX	P3	unknown	Capecitabine (NX) Versus Docetaxel Plus Capecitabine (TX) as 1-line Chemotherapy on Metastatic Breast Cancer (MBC)

Extensive Stage Small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT01155258	—	P1	completed	Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors

Myeloma (1)

NCT	Acronym	Phase	Status	Title
NCT01220375	PAV	P2	completed	PAV-trial: Plerixafor and Chemotherapy With Vinorelbine for Stem Cell Mobilization in Patients With Myeloma

Metastatic Non Small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT01060514	NSCLC	P1	terminated	Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer

Head and Neck Neoplasms (1)

NCT	Acronym	Phase	Status	Title
NCT01020864	CECAVI	P2	withdrawn	Cetuximab in Combination With Chemotherapy for Patients With Head and Neck Cancer

Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT01026220	—	P3	completed	Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma

BRMS1 (1)

NCT	Acronym	Phase	Status	Title
NCT01050322	GLICO-0801	P2	completed	Safety Study in Subjects With Metastatic Breast Cancer Who Progressed After Taxanes Treatment.

HER2/Neu Over-expressing Locally Advanced Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT01007942	BOLERO-3	P3	completed	Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer

Chemotherapeutic Agent Toxicity (1)

NCT	Acronym	Phase	Status	Title
NCT01097317	—	P2	unknown	First-Line Chemotherapy With or Without Neuromuscular Electrical Stimulation in Treating Patients With Non-Small Cell Lung Cancer

Advanced Malignant Solid Tumors (1)

NCT	Acronym	Phase	Status	Title
NCT00958724	—	P1	completed	Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors

Malignant Solid Tumour (1)

NCT	Acronym	Phase	Status	Title
NCT00801151	—	P1	terminated	Vorinostat in Combination With Vinorelbine in Patients With Advanced Cancer

Non-Squamous Non-Small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT00773188	—	P1	completed	A Feasibility Trial of Avastin (Bevacizumab) in Combination With Concomitant Chemoradiation (Cisplatin and Vinorelbine) in Patients With Locally Advanced Non-Squamous Non-Small Cell Lung Cancer.

Nonhematologic Malignancies (1)

NCT	Acronym	Phase	Status	Title
NCT00641160	—	P1	unknown	Safety Study of Oral Vinorelbine in Subjects With Non-Hematologic Malignancies

Advanced Solid Tumors (1)

NCT	Acronym	Phase	Status	Title
NCT01220284	—	P1	unknown	Satraplatin and Vinorelbine in Advanced Solid Tumors

Recurrent Non-Small Cell Lung Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT00602797	—	P2	completed	Vinorelbine Tartrate and Paclitaxel in Treating Older Patients With Advanced Non-Small Cell Lung Cancer

Stage IB Lung Non-Small Cell Carcinoma AJCC v7 (1)

NCT	Acronym	Phase	Status	Title
NCT00324805	—	P3	completed	Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

Lung Cancer, Non-Small Cell (1)

NCT	Acronym	Phase	Status	Title
NCT00455572	—	P1	terminated	Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer

Sarcoma (1)

NCT	Acronym	Phase	Status	Title
NCT00379457	—	P3	unknown	Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma

Advanced Neoplasm (1)

NCT	Acronym	Phase	Status	Title
NCT00908869	METRO1	P1	completed	Combination of Continuous Low Doses of Vinorelbine, Cyclophosphamide and Interferon Alpha 2b (" Metronomic Chemotherapy ") for Antiangiogenic and Antivascular Effect. Trial With Pharmacodynamic Study in Adult Advanced Neoplasm

Childhood Favorable Prognosis Hodgkin Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT00302003	—	P3	completed	Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma

Lung Neoplasm (1)

NCT	Acronym	Phase	Status	Title
NCT00295672	VINCR	P2	completed	Oral Vinorelbine and Cisplatin and Concurrent Radiotherapy After Induction Chemotherapy in Locally Advanced NSCLC.

Non-Hodgkin's Lymphoma (CD20+) (1)

NCT	Acronym	Phase	Status	Title
NCT00280878	—	P2	completed	Rituximab in Combination With Outpatient Therapy for CD20+ Lymphoma

Stage IV (Metastatic) Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT00140140	—	P1/P2	terminated	A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer

Estrogen Receptor-positive Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT00194792	—	P2	terminated	Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer

Malignant Pleural Mesothelioma (1)

NCT	Acronym	Phase	Status	Title
NCT00272558	—	P2	completed	Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma

Non-Small-Cell Lung Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT00256711	INVITE	P2	completed	Phase II Iressa Versus Vinorelbine (INVITE)

Lymphoma, Non-Hodgkin (1)

NCT	Acronym	Phase	Status	Title
NCT00088530	NHL	P3	completed	BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)

Diffuse Large B-Cell Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT00842595	—	P2	completed	Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive Lymphomas

Rhabdomyosarcomas (1)

NCT	Acronym	Phase	Status	Title
NCT00180947	—	P2	unknown	Study of Vinorelbine and Cyclofosfamide Among Patients With Refractory Tumours or in Relapse

Cervical Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT00064077	—	P3	completed	Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix

Metastatic Melanoma (1)

NCT	Acronym	Phase	Status	Title
NCT00256282	—	P2	completed	Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma

Non Small Cell Lung Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT00193921	—	P2	completed	Chemoradiotherapy in Patients With Localised Lung Cancer

Sarcoma, Soft Tissue (1)

NCT	Acronym	Phase	Status	Title
NCT00134641	—	P2	completed	Study of Gemcitabine and Vinorelbine in Soft Tissue Sarcomas

Stage IIIb Non-small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT00042315	NSCLC	P3	terminated	A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Vinorelbine as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC)

NSCLC Stage IIIB (1)

NCT	Acronym	Phase	Status	Title
NCT00198432	—	P2	completed	Chemoradiotherapy of NSCLC Stage IIIB

Metastatic Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT00026494	—	P1/P2	completed	Temozolomide and Vinorelbine in Treating Patients With Recurrent Brain Metastases

Male Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT00017394	—	P2	completed	Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast Cancer

Small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT00401609	G-Step	P1/P2	completed	G-Step: Gemcitabine Based Small-cell Lung Cancer Treatment in Elderly Patients

Esophageal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT00215462	—	P2	completed	Vinorelbine in Unresectable or Metastatic Esophageal and Gastric Adenocarcinoma

Breast (1)

NCT	Acronym	Phase	Status	Title
NCT00277069	—	P1/P2	completed	Phase I-II Study of Carboplatin, Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer

Adenocarcinoma of the Lung (1)

NCT	Acronym	Phase	Status	Title
NCT00005838	—	P3	completed	Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery

Melanoma (Skin) (1)

NCT	Acronym	Phase	Status	Title
NCT00003828	S9804	P2	completed	S9804: Vinorelbine in Treating Patients With Stage IV Melanoma

Kidney Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT00003584	—	P2	completed	Combination Chemotherapy With or Without Prednisone in Treating Patients With Recurrent and/or Metastatic Kidney Cancer

Brain and Central Nervous System Tumors (1)

NCT	Acronym	Phase	Status	Title
NCT00003234	—	P2	completed	Vinorelbine in Treating Children With Recurrent or Refractory Cancers

Bladder Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT00002949	—	P1	completed	Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis

Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation (1)

NCT	Acronym	Phase	Status	Title
NCT02985658	—	N/A	no longer available	Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer

Vinorelbine pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

Acronym	NCT	Phase	Status	Indication	Enrollment	PubMed
PADMA	NCT03355157	P4	completed	Metastatic Breast Cancer	130	—
VIVOS	NCT01848613	P4	completed	Non-small Cell Lung Cancer Metastatic	120	—
INV181	NCT00372476	P4	completed	Breast Cancer	33	PMID 25171229
IR RMS	NCT07466316	P3	recruiting	Rhabdomyosarcoma	342	—
COMET	NCT06908993	P3	recruiting	Advanced Non Small Cell Lung Cancer	133	—
MK-2870	NCT06459180	P3	active not recruiting	Cervical Cancer	686	—
MPDL3280A	NCT02486718	P3	active not recruiting	Non-Small Cell Lung Cancer	1,280	PMID 37903590
TROPION-Lung12	NCT06564844	P3	active not recruiting	Non-small Cell Lung Cancer	25	PMID 40976544
ICC	NCT05104866	P3	active not recruiting	Breast Cancer	732	PMID 37387213
IMMU-132	NCT04639986	P3	active not recruiting	Metastatic Breast Cancer	331	PMID 39354196
ALPHABET	NCT05063786	P3	active not recruiting	Advanced Breast Cancer	27	PMID 35465733
BEGEV	NCT07450508	P3	completed	Classical Hodgkin Lymphoma Relapsed	88	—
innovaTV 301	NCT04697628	P3	completed	Cervical Cancer	502	PMID 38959480
NEOCRTEC308	NCT02465736	P3	unknown	Esophageal Squamous Cell Carcinoma	610	PMID 23274533
CheckMate 816	NCT02998528	P3	completed	Non Small Cell Lung Cancer	505	PMID 40454642
N2	NCT02974426	P3	terminated	Non-small Cell Lung Cancer Stage IIIA	132	PMID 25667283
IPSOS	NCT03191786	P3	completed	Non-Small Cell Lung Cancer	453	PMID 40706710
TROPiCS-02	NCT03901339	P3	completed	Metastatic Breast Cancer	543	PMID 32946924
ARCTIC	NCT02352948	P3	completed	Non - Small Cell Lung Cancer NSCLC	597	PMID 32201234
PRECIOUS	NCT02514681	P3	completed	HER2-positive Locally Advanced or Metastatic Breast Cancer	226	PMID 39854662
PROMISE-meso	NCT02991482	P3	completed	Pleural Mesothelioma Malignant Advanced	144	PMID 12860938
BRAVA	NCT04943627	P3	withdrawn	Advanced Cancer	0	—
EPIC	NCT03402048	P3	unknown	Stage IV, NSCLC	567	—
Toco-Pulm	NCT02644252	P3	terminated	Lung Cancer	79	—
ADJUVANT	NCT01405079	P3	unknown	Non-small Cell Lung Cancer	222	PMID 33332190
ASCENT	NCT02574455	P3	completed	Breast Cancer	529	PMID 33070624
MK-3475	NCT02555657	P3	completed	Metastatic Triple Negative Breast Cancer	622	PMID 33676601
RCTACSCNSCLC	NCT03656393	P3	unknown	NSCLC	48	—
ATTAIN	NCT02915744	P3	completed	Metastasis	178	PMID 31074641
VICTORIANE	NCT02730091	P3	terminated	Breast Cancer	98	—
ATTILA	NCT03811418	P3	withdrawn	Advanced Breast Cancer	0	PMID 25693012
CARIN	NCT00868634	P3	completed	Metastatic Breast Cancer	600	—
NX	NCT01126138	P3	unknown	Carcinoma, Invasive Ductal, Breast	200	PMID 12065558
BOLERO-3	NCT01007942	P3	completed	HER2/Neu Over-expressing Locally Advanced Breast Cancer	569	PMID 24742739
PROCLAIM	NCT00686959	P3	completed	Non Small Cell Lung Cancer	598	PMID 31125266
FLEX	NCT00148798	P3	completed	Non Small Cell Lung Cancer (NSCLC)	1,861	PMID 19410716
NSCLC	NCT00298415	P3	completed	NSCLC	451	PMID 21831418
NHL	NCT00088530	P3	completed	Lymphoma, Non-Hodgkin	140	PMID 22652183
DISTAL-2	NCT00345059	P3	terminated	Advanced Non-Small Cell Lung Cancer	84	PMID 18632181
NSCLC	NCT00441922	P3	completed	Non Small Cell Lung Cancer	166	—
NSCLC	NCT00042315	P3	terminated	Stage IIIb Non-small Cell Lung Cancer	490	—
IMMUNOLIFE2	NCT07001618	P2	recruiting	NSCLC (Advanced Non-small Cell Lung Cancer)	162	—
SPRING	NCT06692491	P2	not yet recruiting	Rare Tumour	200	—
DELUMA	NCT06875128	P2	recruiting	Metastatic Breast Cancer in the Liver	90	—
ASPEN-09-03	NCT07007559	P2	recruiting	Breast Cancer, Metastatic	120	—
ALTER-02	NCT07137884	P2	not yet recruiting	Rhabdomyosarcoma Recurrent	150	—
ORIENTA	NCT06102824	P2	recruiting	HER2-negative Breast Cancer	252	—
ATREZZO	NCT04759248	P2	active not recruiting	Breast Cancer	55	—
CAMPFIRE	NCT05999994	P2	recruiting	Neoplasms	105	—
AZALEA	NCT06690840	P2	recruiting	Triple Negative Breast Cancer	45	—
EASOVCWDITHABC	NCT06653972	P2	not yet recruiting	Her2-negative Metastatic Breast Cancer	30	—
ORCHID	NCT04296162	P2	completed	Breast Cancer	182	—
TrasTUCAN	NCT05583110	P2	terminated	HER2-positive Metastatic Breast Cancer	13	—
BRIDGE	NCT04765709	P2	terminated	Non-small Cell Lung Cancer Stage III	10	PMID 18500231
DIPG	NCT03620032	P2	unknown	Diffuse Intrinsic Pontine Glioma	54	PMID 24560760
MOCCCA	NCT03442673	P2	completed	Multiple Myeloma	137	PMID 39548306
CheckMate 9TN	NCT03770299	P2	withdrawn	Non-Small Cell Lung Cancer	0	—
VEX	NCT04304352	P2	unknown	Advanced Breast Cancer	162	—
VinCaT	NCT00431704	P2	unknown	Metastatic Breast Cancer	39	—
RIGHT Choice	NCT03839823	P2	completed	Breast Cancer	222	PMID 38771995
DURATION	NCT03345810	P2	completed	Carcinoma, Non-Small-Cell Lung	200	PMID 32321565
METEORA-II	NCT02954055	P2	completed	Breast Cancer	140	PMID 37440239
Pyrotinib	NCT03933982	P2	unknown	Breast Cancer	30	—
VinMetAtezo	NCT03801304	P2	completed	Non-small Cell Lung Cancer	80	PMID 31894704
N2	NCT02977169	P2	unknown	Non-small Cell Lung Cancer Stage IIIA	300	PMID 18439766
QUADRUPLE THREAT	NCT02489903	P2	completed	Small Cell Carcinoma	139	PMID 33569311
VIM	NCT02139904	P2	completed	Mesothelioma	154	PMID 35706488
OVIMA-1210	NCT02197637	P2	completed	Low-Grade Glioma	39	—
EORTC1616	NCT03482362	P2	completed	Colon Cancer	1	—
NORA	NCT02709720	P2	completed	Lung Cancer	68	PMID 33453470
MPM	NCT02610140	P2	completed	Mesothelioma	248	PMID 35358455
VinoMetro	NCT03007992	P2	completed	Metastatic Breast Cancer	9	PMID 33743073
S1VSNP	NCT02223611	P2	unknown	Non-small Cell Lung Cancer Stage Ⅱ	100	—
ONC-MANILA12	NCT02176369	P2	completed	Non-small Cell Lung Cancer Stage IIIB	120	—
VICTOR3	NCT03358004	P2	terminated	Triple Negative Breast Cancer	4	—
HS-110	NCT02117024	P2	terminated	Non Small Cell Lung Cancer	66	—
ViGeM	NCT02791373	P2	completed	Multiple Myeloma	136	PMID 8649495
LV	NCT01730677	P2	unknown	Metastatic Breast Cancer	150	PMID 31690831
TNM	NCT02144194	P2	unknown	Breast Cancer	65	—
HighTySy	NCT02919462	P2	terminated	Carcinoma, Non-Small-Cell Lung	2	—
CHEOPS	NCT02585388	P2	terminated	Breast Cancer	120	—
VicTORia	NCT01520103	P2	completed	Her2-negative Metastatic Breast Cancer	139	PMID 31115844
RACCOSA	NCT01029678	P2	completed	Non Small Cell Lung Cancer	48	—
VITAL	NCT01013740	P2	completed	Cancer	112	PMID 26384789
CONTEST	NCT01784549	P2	unknown	Non Small Cell Lung Cancer	168	—
VELVET	NCT01565083	P2	completed	Breast Cancer	213	PMID 27955684
NEOSCAN	NCT01443078	P2	completed	Lung Cancer	42	—
XeNa	NCT01941771	P2	completed	Breast Cancer	110	—
BIBW2992	NCT01325428	P2	completed	Breast Neoplasms	26	PMID 27923043
OVINTRA	NCT01242449	P2	completed	Breast Cancer	10	—
HER2	NCT01441596	P2	completed	Breast Neoplasms	121	PMID 26596672
Lung-TRIO	NCT01038037	P2	terminated	Non Small Cell Lung Cancer	23	—
PAV	NCT01220375	P2	completed	Myeloma	44	—
NVBOX	NCT01528826	P2	unknown	Breast Cancer	35	PMID 25648299
CERTO	NCT00842712	P2	completed	Carcinoma, Non-Small-Cell Lung	232	PMID 25939894
S0102	NCT00015938	P2	completed	Breast Cancer	95	—
CECAVI	NCT01020864	P2	withdrawn	Head and Neck Neoplasms	0	—
TOP0703	NCT00545948	P2	terminated	Carcinoma, Non-Small-Cell Lung	31	PMID 16899777
GLICO-0801	NCT01050322	P2	completed	BRMS1	142	—
MBC	NCT00629148	P2	completed	Breast Cancer	60	—
TOLEDO	NCT00434668	P2	completed	Non-small Cell Lung Cancer	99	—
NSCLC	NCT01687439	P2	completed	Non-small Cell Lung Cancer	15	—
S0027	NCT00026156	P2	completed	Lung Cancer	125	PMID 17409914
VINCR	NCT00295672	P2	completed	Lung Neoplasm	60	PMID 15713523
MILES-02	NCT00401492	P2	completed	Non Small Cell Lung Cancer	159	PMID 17925563
S9806	NCT00003587	P2	completed	Lung Cancer	204	PMID 15297403
HERVIN	NCT00401427	P2	completed	Metastatic Breast Cancer	50	PMID 17374151
NSCLC	NCT00168883	P2	unknown	Carcinoma, Non-Small-Cell Lung	80	—
GON	NCT00271271	P2	completed	Non Small Cell Lung Cancer	40	—
TIE	NCT00678964	P2	unknown	Non-Small Cell Lung Cancer	260	—
INVITE	NCT00256711	P2	completed	Non-Small-Cell Lung Carcinoma	192	PMID 18779612
S9804	NCT00003828	P2	completed	Melanoma (Skin)	24	PMID 15073859

Terminated and withdrawn Vinorelbine trials (65)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

NCT05711628withdrawnA Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma
NCT05238831withdrawnSMMART Adaptive Clinical Treatment (ACT) Trial
NCT05583110terminatedEfficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer
NCT04765709terminatedDurvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC
NCT06137651withdrawnTrotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal Metastasis
NCT03770299withdrawnAn Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease
NCT02974426terminatedTo Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer
NCT03393741terminatedPharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy
NCT05134194terminatedA Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer
NCT02229149terminatedPhase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer
NCT03386721terminatedBasket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors
NCT04943627withdrawnBalstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)
NCT02644252terminatedTocotrienol as a Nutritional Supplement in Patients With Advanced Lung Cancer
NCT02795884withdrawnAdjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR Mutation
NCT03891173terminatedA Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma
NCT02730091terminatedA Open Study of Metronomic Oral Vinorelbine in Combination With Aromatase Inhibitors for the Treatment of Postmenopausal Women With Hormone Receptor Positive,HER2-negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease
NCT03811418withdrawnA Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer
NCT02658084terminatedVinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer
NCT03358004terminatedthe Role of Two Different Metronomic Chemotherapy Regimens in Locally Advanced or Metastatic Triple Negative Breast Cancer Patients (TNBC) as Maintenance Therapy After First Line Treatment
NCT02985203terminatedOral Navelbine and Cisplatin Followed by Metronomic Oral Navelbine in Non-Small Cell Lung Cancer
NCT02117024terminatedA Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer
NCT01137994withdrawnA Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
NCT02331251terminatedStudy of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)
NCT01185509terminatedTrastuzumab and Vinorelbine in Advanced Breast Cancer
NCT02213744terminatedMM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients
NCT02919462terminatedOpen-label, Multicenter, Randomized Phase II Trial of Treatment With Cisplatin and Pemetrexed or Cisplatin and Oral Vinorelbine in Chemotherapy Naïve Patients Affected by Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer With High Thymidylate Synthase Expression
NCT02585388terminatedAddition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer.
NCT00003622withdrawnVinorelbine Plus Paclitaxel in Treating Patients With Metastatic Prostate Cancer That Is Refractory to Hormone Therapy
NCT00920153terminatedThree Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma
NCT01238029terminatedDose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast Cancer
NCT01161368terminatedA Study Evaluating the Efficacy and Safety of Lapatinib + Vinorelbine in ErbB2 Positive Metastatic Breast Cancer Patients
NCT01038037terminatedFirst-Line Chemotherapy and Panitumumab in Advanced Non-Small Cell Lung Cancer
NCT01531764terminatedBIBW 2992 (Afatinib) and Vinorelbine
NCT01060514terminatedPazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer
NCT00455572terminatedCancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer
NCT00863512terminatedChemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer
NCT00881387withdrawnRituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to Treatment
NCT00709618terminatedLapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects
NCT01020864withdrawnCetuximab in Combination With Chemotherapy for Patients With Head and Neck Cancer
NCT00545948terminatedAdjuvant Cisplatin With Either Genomic-Guided Vinorelbine or Pemetrexed for Early Stage Non-Small-Cell Lung Cancer
NCT01254136terminatedSafety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer
NCT00705549terminatedIndividualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer
NCT00194792terminatedHormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer
NCT00476827terminatedA Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain
NCT00754702terminatedVinorelbine Metronomic Plus Lapatinib for Overexpressing HER-2 Metastatic Breast Cancer
NCT00235235terminatedA Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer
NCT00597116terminatedAn Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma
NCT00694200terminatedVinorelbine Metronomic Plus Bevacizumab as Salvage Therapy for Breast Cancer
NCT00801151terminatedVorinostat in Combination With Vinorelbine in Patients With Advanced Cancer
NCT00088985terminatedVaccine Therapy, Trastuzumab, and Vinorelbine in Treating Women With Locally Recurrent or Metastatic Breast Cancer
NCT00176488terminatedEpirubicin and Vinorelbine in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer
NCT00130507terminatedBenefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab
NCT00169104terminatedEffects of Granulocyte Colony-stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function
NCT00453635terminatedStudy With Docetaxel, Carboplatin and Herceptin Versus Vinorelbine and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients
NCT00041470terminatedNavelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial
NCT00345059terminatedThe DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer
NCT00140140terminatedA Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer
NCT00403988terminatedVinorelbine and Oxaliplatin (Vinox) With or Without Trastuzumab (Herceptin®) in Advanced Breast Carcinoma
NCT00225173terminatedCombination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease
NCT00075673terminatedVinorelbine and Celecoxib in Treating Women With Relapsed or Metastatic Breast Cancer
NCT00054197terminatedPolyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
NCT00042315terminatedA Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Vinorelbine as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC)
NCT00055887withdrawnChemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer
NCT00049660terminatedCapecitabine Compared With Vinorelbine in Treating Women With Metastatic Breast Cancer
NCT00004093terminatedCombination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

All Vinorelbine trials (426)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT ID	Acronym	Title	Phase	Status	Enrollment	Sponsor	Started
NCT06023641		Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease	P2	recruiting	135	St. Jude Children's Research Hospital	Mar 2024
NCT07021989		ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma	P2	recruiting	38	Michael Spinner, MD	Aug 2026
NCT07001618	IMMUNOLIFE2	Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer	P2	recruiting	162	Gustave Roussy, Cancer Campus, Grand Paris	Nov 2025
NCT03456076		A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer	P3	active not recruiting	257	Hoffmann-La Roche	Aug 2018
NCT07466316	IR RMS	A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)	P3	recruiting	342	Children's Oncology Group	Jul 2026
NCT06255392		Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer	P3	recruiting	200	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Jun 2024
NCT02813135	ESMART	European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors	P1/P2	recruiting	472	Gustave Roussy, Cancer Campus, Grand Paris	Aug 2016
NCT06435429		A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer	P3	recruiting	550	Jazz Pharmaceuticals	Aug 2024
NCT04625907	FaR-RMS	FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma	P1/P2	recruiting	1,672	University of Birmingham	Sep 2020
NCT06632327		Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer	P3	active not recruiting	37	Alliance for Clinical Trials in Oncology	Dec 2024
NCT07406542		A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer	P3	not yet recruiting	400	CSPC Megalith Biopharmaceutical Co.,Ltd.	Apr 2026
NCT07533123		A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care	P3	recruiting	364	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	Mar 2026
NCT06692491	SPRING	Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS	P2	not yet recruiting	200	Peking University Shenzhen Hospital	Jan 2025
NCT06875128	DELUMA	Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease	P2	recruiting	90	Delcath Systems Inc.	Jan 2026
NCT05487391		A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.	P3	recruiting	632	Qilu Pharmaceutical Co., Ltd.	Dec 2022
NCT06079983		JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects	P3	recruiting	400	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	Dec 2023
NCT07007559	ASPEN-09-03	ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer	P2	recruiting	120	ALX Oncology Inc.	Dec 2025
NCT07137884	ALTER-02	Anlotinib Hydrochloride Capsules in Maintenance Treatment for Intermediate-High Risk Rhabdomyosarcoma in Children	P2	not yet recruiting	150	Sun Yat-sen University	Oct 2025
NCT07420439		Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease	P2	not yet recruiting	108	Intergroupe Francophone de Cancerologie Thoracique	Sep 2026
NCT06500494	VINOREAL	To Describe How Well Vinorelbine Given Orally Works in Patients With a Breast Cancer After 2 Years of Treatment	—	active not recruiting	368	Pierre Fabre Medicament	Sep 2024
NCT06383767		A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer	P3	recruiting	378	Qilu Pharmaceutical Co., Ltd.	Jul 2024
NCT05901935		DP303c in Patients With HER2-positive Advanced Breast Cancer	P3	not yet recruiting	420	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Jul 2023
NCT06908993	COMET	Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated	P3	recruiting	133	Intergroupe Francophone de Cancerologie Thoracique	Dec 2025
NCT07461454		YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer	P3	recruiting	376	MediLink Therapeutics (Suzhou) Co., Ltd.	Mar 2026
NCT06102824	ORIENTA	Organoid-based Functional Precision Therapy for Advanced Breast Cancer	P2	recruiting	252	Guangdong Provincial People's Hospital	Oct 2024
NCT05711628		A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma	P3	withdrawn	0	National Cancer Institute (NCI)	Aug 2023
NCT07088263		Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer	P3	recruiting	192	Sun Yat-sen University	Sep 2025
NCT06459180	MK-2870	A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)	P3	active not recruiting	686	Merck Sharp & Dohme LLC	Jul 2024
NCT06268652		Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer	P3	recruiting	302	Sun Yat-sen University	Jan 2024
NCT06908304		A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC	P3	recruiting	300	Maia Biotechnology	Dec 2025
NCT06382142		A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)	P3	active not recruiting	418	Sichuan Baili Pharmaceutical Co., Ltd.	Jun 2024
NCT06343948		A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)	P3	active not recruiting	383	Sichuan Baili Pharmaceutical Co., Ltd.	Apr 2024
NCT06081959		Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer	P3	recruiting	376	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	Oct 2023
NCT05856383	HER2-VIP	Efficacy and Safety of Inetetamab Combined With Pyrotinib and Vinorelbine in ABC	—	recruiting	100	Zhejiang Cancer Hospital	Mar 2022
NCT04299113		Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma	P1	active not recruiting	14	Jonsson Comprehensive Cancer Center	May 2020
NCT06202261		A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer	P1/P2	recruiting	154	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Apr 2023
NCT04388839		Evolutionary Therapy for Rhabdomyosarcoma	P2	active not recruiting	12	H. Lee Moffitt Cancer Center and Research Institute	Dec 2020
NCT03618550		Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma	P2	recruiting	257	Memorial Sloan Kettering Cancer Center	Aug 2018
NCT02486718	MPDL3280A	Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]	P3	active not recruiting	1,280	Hoffmann-La Roche	Oct 2015
NCT04994132		A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma	P3	active not recruiting	113	Children's Oncology Group	Sep 2021
NCT04759248	ATREZZO	Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer	P2	active not recruiting	55	SOLTI Breast Cancer Research Group	Mar 2021
NCT06564844	TROPION-Lung12	A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features	P3	active not recruiting	25	AstraZeneca	Oct 2024
NCT06519370		FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer	P3	active not recruiting	350	Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.	Aug 2024
NCT06489808		Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL	P2	recruiting	89	Institute of Hematology & Blood Diseases Hospital, China	May 2024
NCT05999994	CAMPFIRE	A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer	P2	recruiting	105	Eli Lilly and Company	Jan 2020
NCT03414658		The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer	P2	active not recruiting	100	Adrienne G. Waks	Jun 2018
NCT06377566		A Study of BV-AVD in People With Bulky Hodgkin Lymphoma	P2	recruiting	71	Memorial Sloan Kettering Cancer Center	Apr 2024
NCT06690840	AZALEA	Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients	P2	recruiting	45	European Institute of Oncology	Mar 2025
NCT06229067		Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer	P2	not yet recruiting	182	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Jan 2024
NCT05104866	ICC	A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)	P3	active not recruiting	732	AstraZeneca	Oct 2021
NCT04922658		Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer	P2	active not recruiting	76	Affiliated Cancer Hospital & Institute of Guangzhou Medical University	Jun 2020
NCT04639986	IMMU-132	Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)	P3	active not recruiting	331	Gilead Sciences	Nov 2020
NCT02567435		Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma	P3	active not recruiting	325	National Cancer Institute (NCI)	Jun 2016
NCT06576635	LUNG-05	LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic Patients	N/A	recruiting	29	University of Illinois at Chicago	Dec 2024
NCT06653972	EASOVCWDITHABC	Efficacy and Safety of a Two-week Dosing Regimen of Vinorelbine Combined with Liposomal Doxorubicin in the Treatment of HER2-negative Advanced Breast Cancer	P2	not yet recruiting	30	Wang Jiayu	Nov 2024
NCT05063786	ALPHABET	Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)	P3	active not recruiting	27	Spanish Breast Cancer Research Group	Sep 2021
NCT04922008		Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS-C/D)	P2	unknown	356	Fudan University	Jul 2021
NCT06540950		Efficacy and Safety of Concurrent Chemoradiotherapy With Oral Vinorelbine in Patients With Non-small Cell Lung Cancer	P2	active not recruiting	47	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Mar 2023
NCT05238831	ACT	SMMART Adaptive Clinical Treatment (ACT) Trial	Early P1	withdrawn	0	OHSU Knight Cancer Institute	Jan 2023
NCT04296162	ORCHID	Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID)	P2	completed	182	Fudan University	Mar 2020
NCT06857747		Disitamab Vedotin in Combination with Metronomic Chemotherapy in Advanced HER2-expressing Breast Cancer.	N/A	unknown	40	QIAO LI	Mar 2025
NCT07450508	BEGEV	Study of Bendamustine, Gemcitabine and Vinorelbine Regimen in Relapsed/Refractory Classical Hodgkin Lymphoma	P3	completed	88	Cairo University	Apr 2024
NCT06015126		Efficacy and Safety of Metronomic Oral Vinorelbine Plus Anlotinib in HER2-negative Metastatic Breast Cancer Patients	N/A	unknown	60	Yan Xue	Oct 2022
NCT04145349	LY3009806	CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor	P1/P2	completed	30	Eli Lilly and Company	Jan 2020
NCT04697628	innovaTV 301	Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer	P3	completed	502	Seagen, a wholly owned subsidiary of Pfizer	Feb 2021
NCT06143553		Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer	P3	recruiting	168	Shanghai Yizhong Pharmaceutical Co., Ltd.	Sep 2023
NCT05823623		Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer	P2	unknown	30	The First Affiliated Hospital with Nanjing Medical University	Feb 2022
NCT03703427		Capecitabine Versus Vinorelbine in High Risk Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy	P2	unknown	200	Zhiyong Yu	Nov 2018
NCT06260553		Metronomic Oral Vinorelbine Combination With Tislelizumab in EGFR/ALK-negative Advanced NSCLC	P2	unknown	40	Fujian Cancer Hospital	Feb 2024
NCT02465736	NEOCRTEC308	Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer (NEOCRTEC308)	P3	unknown	610	Sun Yat-sen University	Jul 2015
NCT05583110	TrasTUCAN	Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer	P2	terminated	13	Spanish Breast Cancer Research Group	Mar 2023
NCT06533722		Adaptive Therapy for Post-Second-Line Advanced Breast Cancer	P2	completed	10	Sun Yat-sen University	Aug 2024
NCT04624984		PD-1 Inhibitor or PD-1 Inhibitor Plus GVD for Relapsed/Refractory CHL	P2	unknown	42	Sun Yat-sen University	Apr 2021
NCT03443128		Vinorelbine for Recurrent ALCL-2017	P2	completed	20	Children's Cancer Group, China	Nov 2016
NCT06355037		Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer	P2	unknown	10	Fudan University	May 2024
NCT02344472		Detect V / CHEVENDO (Chemo vs. Endo)	P3	unknown	271	Prof. Wolfgang Janni	Sep 2015
NCT00324805		Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery	P3	completed	1,501	National Cancer Institute (NCI)	Jul 2007
NCT04765709	BRIDGE	Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC	P2	terminated	10	Mario Negri Institute for Pharmacological Research	Sep 2021
NCT06355024		Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer	P2	completed	10	Fudan University	May 2024
NCT04848454		Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy	P2	unknown	30	Peking University First Hospital	Nov 2021
NCT04143906		Vinorelbine/Carboplatin Versus Gemcitabine/Carboplatin in Metastatic Breast Cancer	P2	unknown	200	Shandong Cancer Hospital and Institute	Oct 2019
NCT03270007		Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy	P4	unknown	304	Tao OUYANG	Nov 2017
NCT04400695		A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2	P3	unknown	366	RemeGen Co., Ltd.	Sep 2020
NCT03518606	MOVIE	Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours	P1/P2	completed	126	UNICANCER	Jun 2018
NCT02998528	CheckMate 816	A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)	P3	completed	505	Bristol-Myers Squibb	Mar 2017
NCT05296577		Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer	P2	unknown	134	Henan Cancer Hospital	Mar 2022
NCT03620032	DIPG	Study of Re-irradiation at Relapse Versus RT and Multiple Elective rt Courses	P2	unknown	54	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano	Nov 2015
NCT02892123		Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers	P1	completed	279	Jazz Pharmaceuticals	Sep 2016
NCT05603013		Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)	P2	unknown	45	Second Affiliated Hospital of Soochow University	Oct 2022
NCT04681911		Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer	P2	unknown	71	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	Sep 2020
NCT03355157	PADMA	A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).	P4	completed	130	GBG Forschungs GmbH	Mar 2018
NCT04963595		Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer	P2	unknown	100	Zhiyong Yu	Aug 2021
NCT05663177		Almonertinib Plus Metronomic Oral Vinorelbine	—	unknown	40	Fujian Cancer Hospital	Dec 2022
NCT03442673	MOCCCA	Chemotherapy and G-CSF for Mobilization	P2	completed	137	Insel Gruppe AG, University Hospital Bern	Sep 2018
NCT03242616		PemVin vs Vin in Previously Treated Metastatic Breast Cancer	P2	completed	17	Seoul National University Hospital	Feb 2017
NCT05764941		Inetetamab Combined With Pyrotinib and Vinorelbine as First-line to Third-line Treatment for HER2-positive Metastatic Breast Cancer	—	unknown	100	The First Affiliated Hospital with Nanjing Medical University	Jan 2020
NCT06137651		Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal Metastasis	P1	withdrawn	0	Northwestern University	Dec 2023
NCT03770299	CheckMate 9TN	An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease	P2	withdrawn	0	Bristol-Myers Squibb	Jan 2021
NCT02974426	N2	To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer	P3	terminated	132	Shanghai Chest Hospital	Nov 2016
NCT03393741		Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy	—	terminated	5	University of Wisconsin, Madison	Jan 2018
NCT06373744		Metronomic Chemotherapy in a Real-world Population of Advanced Breast Cancer Patients	—	completed	597	Sun Yat-sen University	Jan 2023
NCT04389073		Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine	P2	unknown	138	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Apr 2020
NCT04262804		A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC	P2	unknown	123	Zai Lab (Shanghai) Co., Ltd.	Jan 2020
NCT04304352	VEX	Metronomic Oral Chemotherapy With Cyclophosphamide, Capecitabine and Vinorelbine in Metastatic Breast Cancer Patients	P2	unknown	162	European Institute of Oncology	Jul 2011
NCT00431704	VinCaT	VinCaT: Vinorelbine, Carboplatin and Trastuzumab in Advanced Her-2 Positive Breast Cancer	P2	unknown	39	National Cancer Institute, Naples	Oct 2007
NCT04021992		GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL	P2	unknown	48	Sun Yat-sen University	Jul 2019
NCT04605575		Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer	P2	unknown	208	Sun Yat-sen University	May 2020
NCT03191786	IPSOS	A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy	P3	completed	453	Hoffmann-La Roche	Sep 2017
NCT03901339	TROPiCS-02	Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer	P3	completed	543	Gilead Sciences	May 2019
NCT02352948	ARCTIC	A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer	P3	completed	597	AstraZeneca	Jan 2015
NCT03321981		MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.	P2	completed	105	Merus B.V.	Jan 2018
NCT05747326		Oral Vinorelbine and Capecitabine in Advanced HER2-negative Breast Cancer	P2	unknown	30	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Jan 2022
NCT03932526		Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer	P2	unknown	184	Liaoning Cancer Hospital & Institute	Jun 2019
NCT03839823	RIGHT Choice	Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer	P2	completed	222	Novartis Pharmaceuticals	Feb 2019
NCT04745975		Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer	P2	unknown	100	Fudan University	Feb 2021
NCT03381066		A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations.	P3	unknown	225	Yonsei University	Apr 2018
NCT03345810	DURATION	Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)	P2	completed	200	AIO-Studien-gGmbH	Dec 2017
NCT02607215		Platinum Rechallenge in Patients With Platinum-sensitive mTNBC	P2	unknown	84	Fudan University	Nov 2015
NCT05131841		Cipterbin Combined With Vinorelbine in the Treatment of HER2-positive MBC	P4	unknown	60	Zhejiang Cancer Hospital	Jan 2021
NCT05134194		A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer	P3	terminated	1	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	Jan 2022
NCT02954055	METEORA-II	MEtronomic TrEatment Option in Advanced bReast cAncer	P2	completed	140	ETOP IBCSG Partners Foundation	Sep 2017
NCT02555007	NVB Metro	Metronomic Chemotherapy Based on Adaptative Bio-mathematical Model of Oral Vinorelbine in Patients With NSCLC or MPM	P1	completed	30	Assistance Publique Hopitaux De Marseille	Aug 2015
NCT02514681	PRECIOUS	A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer	P3	completed	226	Japan Breast Cancer Research Group	Aug 2015
NCT00574496		Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma	P2	completed	25	Memorial Sloan Kettering Cancer Center	Nov 2007
NCT03397953		Vinorelbine for Recurrent ACLC	P2	completed	20	Children's Cancer Group, China	Nov 2016
NCT03188159		Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer	P2	unknown	36	National University Hospital, Singapore	Jul 2017
NCT03933982	Pyrotinib	A Study of Pyrotinib Plus Vinorelbine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer	P2	unknown	30	Chinese Academy of Medical Sciences	Dec 2018
NCT01026220		Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma	P3	completed	166	Children's Oncology Group	Dec 2009
NCT03801304	VinMetAtezo	Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung Cancer	P2	completed	80	University Hospital, Brest	Jan 2019
NCT04903652		Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast Cancer	P2	completed	30	Tianjin Medical University Cancer Institute and Hospital	Jan 2021
NCT02229149		Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer	P2	terminated	33	US Oncology Research	Dec 2014
NCT06107790		Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast Cancer	P3	completed	570	Zhejiang Hisun Pharmaceutical Co. Ltd.	May 2018
NCT02977169	N2	To Evaluate the Role of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer	P2	unknown	300	Shanghai Chest Hospital	Nov 2016
NCT03997539		A Study of Pyrotinib Plus Vinorelbine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer	P2	unknown	256	Sun Yat-sen University	Aug 2019
NCT03386721		Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors	P2	terminated	256	Hoffmann-La Roche	Feb 2018
NCT03925233		Breast Cancer Treatment Based on Organ-like Culture	—	unknown	300	Xijing Hospital	Jan 2019
NCT02489903	QUADRUPLE THREAT	RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)	P2	completed	139	EpicentRx, Inc.	Jun 2015
NCT02991482	PROMISE-meso	PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma	P3	completed	144	ETOP IBCSG Partners Foundation	Sep 2017
NCT04943627	BRAVA	Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)	P3	withdrawn	0	Agenus Inc.	Aug 2021
NCT04307147		NX in Luminal B Breast Cancer Patients After Neoadjuvant Chemotherapy	P3	unknown	316	Fudan University	Jul 2018
NCT03254654		Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer	P2	completed	66	Fudan University	Aug 2017
NCT04302441		A Study to Evaluate Vinorelbine Plus Capecitabine Combined With Trastuzumab for HER2 Positive Patients Following Neoadjuvant Chemotherapy	P2	unknown	550	Fudan University	Nov 2016
NCT03161054		Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas	P2	completed	21	Fondazione Italiana Linfomi - ETS	Sep 2017
NCT02733380		Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma	P2	unknown	20	Henan Cancer Hospital	May 2016
NCT03402048	EPIC	The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial	P3	unknown	567	University of Turin, Italy	Jul 2012
NCT02139904	VIM	Vinorelbine in Mesothelioma	P2	completed	154	Wales Cancer Trials Unit	Mar 2016
NCT02897986	PROVIN	Study of a Propranolol (HEMANGIOL®) and Oral Metronomic Vinorelbine (NAVELBINE®) Combination for Children and Teenagers With Refractory/Relapsing Solid Tumors	P1	unknown	54	Assistance Publique Hopitaux De Marseille	Jan 2017
NCT02644252	Toco-Pulm	Tocotrienol as a Nutritional Supplement in Patients With Advanced Lung Cancer	P3	terminated	79	Vejle Hospital	Jan 2016
NCT01405079	ADJUVANT	Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation	P3	unknown	222	Guangdong Association of Clinical Trials	Sep 2011
NCT03947242		Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer.	N/A	unknown	48	Henan Cancer Hospital	Jun 2019
NCT03939871		A Study of Fluvestrant Combined With Oral Vinorelbine in Hormone Receptor-positive Advanced Breast Cancer	P2	unknown	30	Chinese Academy of Medical Sciences	Dec 2017
NCT02574455	ASCENT	Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)	P3	completed	529	Gilead Sciences	Nov 2017
NCT02795884		Adjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR Mutation	P3	withdrawn	0	Yonsei University	Jun 2016
NCT02555657	MK-3475	Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)	P3	completed	622	Merck Sharp & Dohme LLC	Oct 2015
NCT02197637	OVIMA-1210	Phase II Trial of Oral Vinorelbine in Children With Recurrent or Progressive Unresectable Low-Grade Glioma	P2	completed	39	Centre Oscar Lambret	May 2014
NCT01683175		Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation	P2	unknown	94	Tianjin Medical University Cancer Institute and Hospital	Aug 2012
NCT03656393	RCTACSCNSCLC	To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung Adenocarcinoma	P3	unknown	48	Shenzhen People's Hospital	Aug 2018
NCT02281708		Multicenter Randomized Controlled Trial Adjuvant Chemotherapy vs Observation in pStage Ib Lung Adenocarcinoma	P3	unknown	1,012	Seoul National University Hospital	Oct 2014
NCT02915744	ATTAIN	A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine	P3	completed	178	Nektar Therapeutics	Nov 2016
NCT02362958		A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer	P2	completed	159	Sun Yat-sen University	Jan 2015
NCT01835236		Trastuzumab & Pertuzumab Followed by T-DM1 in MBC	P2	completed	208	Swiss Cancer Institute	Mar 2013
NCT03891173		A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma	P2	terminated	9	Helix BioPharma Corporation	Feb 2019
NCT04208854	VINORELBINA	Observational Study With Metronomic Oral Vinorelbine in Elderly Patients With Locally Advanced / Metastatic Non-small-cell Lung Cancer (NSCLC)	—	unknown	40	International Group of Endovascular Oncology	Apr 2018
NCT02730091	VICTORIANE	A Open Study of Metronomic Oral Vinorelbine in Combination With Aromatase Inhibitors for the Treatment of Postmenopausal Women With Hormone Receptor Positive,HER2-negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease	P3	terminated	98	Centre Hospitalier Universitaire de Besancon	Feb 2016
NCT03482362	EORTC1616	Vinorelbine in Advanced BRAF-like Colon Cancer	P2	completed	1	The Netherlands Cancer Institute	Mar 2018
NCT03423849		The Maintenance Regimen and Revised Regimen for Advanced Breast Cancer Survivors After First-line Salvage Therapy	P2/P3	unknown	200	Zhiyong Yu	Feb 2018
NCT03652857		Apatinib Combined With Vinorelbine for Non-driver Gene Mutation Non-small Cell Lung Cancer	P2	completed	30	Yongchang Zhang	Jan 2017
NCT02777788	TCM	Curative Study of Chinese Traditional Medicine to Treat Lung Cancer	P2/P3	unknown	120	Shanghai University of Traditional Chinese Medicine	Sep 2014
NCT02709720	NORA	Study of Vinorelbine and Cisplatin as Induction Therapy With Radiotherapy in Patients With Unresectable NSCLC	P2	completed	68	Spanish Lung Cancer Group	Apr 2016
NCT02610140	MPM	Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)	P2	completed	248	Bayer	Dec 2015
NCT00302003		Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma	P3	completed	287	Children's Oncology Group	Feb 2006
NCT03811418	ATTILA	A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer	P3	withdrawn	0	iOMEDICO AG	Jan 2019
NCT03007992	VinoMetro	Metronomic Treatment With Daily Oral Vinorelbine as First-line Chemotherapy in Patients With Advanced/Metastatic Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer	P2	completed	9	Johannes Gutenberg University Mainz	Dec 2016
NCT02628613		Neoadjuvant Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin in Breast Cancer With TEKT4 Variations	P2	completed	91	Fudan University	Dec 2015
NCT02579564		Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients	P3	unknown	134	Xinqiao Hospital of Chongqing	Oct 2016
NCT02223611	S1VSNP	Clinical Observation of S1 Capsule for Stage Ⅱ-ⅢA Non-small Cell Lung Cancer After Complete Resection	P2	unknown	100	Hebei Medical University Fourth Hospital	Dec 2014
NCT02176369	ONC-MANILA12	Maintenance Low Dose Oral Navelbine In Patients With Non Small Cell Lung Cancer - MA.NI.LA Trial	P2	completed	120	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano	Feb 2013
NCT02658084		Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer	P1/P2	terminated	2	University of Miami	Apr 2017
NCT03358004	VICTOR3	the Role of Two Different Metronomic Chemotherapy Regimens in Locally Advanced or Metastatic Triple Negative Breast Cancer Patients (TNBC) as Maintenance Therapy After First Line Treatment	P2	terminated	4	Mario Negri Institute for Pharmacological Research	Jun 2017
NCT01125566		LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment	P3	completed	508	Boehringer Ingelheim	Jun 2010
NCT02225470		Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes	P3	completed	530	Eisai Co., Ltd.	Sep 2013
NCT00706030	HKI-272	Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer	P1/P2	completed	92	Puma Biotechnology, Inc.	Apr 2008
NCT01848613	VIVOS	Study of Patient Preference for Oral or Intravenous Vinorelbine in the Treatment of Advanced NSCLC	P4	completed	120	Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS	Oct 2012
NCT02985203		Oral Navelbine and Cisplatin Followed by Metronomic Oral Navelbine in Non-Small Cell Lung Cancer	P2	terminated	45	Guangdong Association of Clinical Trials	Nov 2016
NCT02117024	HS-110	A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer	P2	terminated	66	Heat Biologics	Jul 2014
NCT02619929	StepUp	Initial Oral Vinorelbine Dosing Schedules in Clinical Routine in Germany and Austria	—	completed	108	Pierre Fabre Pharma GmbH	Feb 2016
NCT01137994		A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer	P2	withdrawn	0	GlaxoSmithKline	Oct 2011
NCT02802748	VENTANA	Phase 0 Study of Metronomic Oral Vinorelbine and Letrozole in HR+/HER2-negative Early Breast Cancer Patients (VENTANA)	Early P1	completed	60	SOLTI Breast Cancer Research Group	Jul 2016
NCT02331251		Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)	P1/P2	terminated	81	Western Regional Medical Center	Dec 2014
NCT01185509		Trastuzumab and Vinorelbine in Advanced Breast Cancer	P2	terminated	31	Dana-Farber Cancer Institute	Nov 2010
NCT00064077		Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix	P3	completed	513	Gynecologic Oncology Group	May 2003
NCT02791373	ViGeM	Vinorelbine and Gemcitabine in Myeloma	P2	completed	136	Insel Gruppe AG, University Hospital Bern	Mar 2014
NCT01749072		Vinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients	P2	unknown	120	Peking Union Medical College Hospital	Dec 2012
NCT01730677	LV	Lapatinib+Vinorelbine vs Vinorelbine HER2 Positive Metastatic Breast Cancer Progressed After Lapatinib/Trastuzumab	P2	unknown	150	National Cancer Center, Korea	Jul 2012
NCT02144194	TNM	Maintenance Oral Vinorelbine or Observation After Vinorelbine-Docetaxel First Line Chemotherapy in Advanced Breast Ca	P2	unknown	65	Cancer Research Group - Collaborative Group, Beirut, Lebanon.	Mar 2012
NCT00266110		Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer	P2	completed	17	UNC Lineberger Comprehensive Cancer Center	Dec 2005
NCT01305941		A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases	P2	completed	32	UNC Lineberger Comprehensive Cancer Center	Sep 2011
NCT01497860		Vinorelbine for Children With Progressive or Recurrent Low-grade Gliomas	P2	completed	13	Eugene Hwang	Jul 2011
NCT01410214		Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations	P2	unknown	80	Chinese Lung Cancer Surgical Group	May 2011
NCT00912275		Lapatinib in Combination With Oral Vinorelbine for Metastatic Breast Cancer	P1/P2	completed	46	National Taiwan University Hospital	Nov 2008
NCT02213744	HERMIONE	MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients	P2/P3	terminated	113	Merrimack Pharmaceuticals	Jul 2014
NCT02919462	HighTySy	Open-label, Multicenter, Randomized Phase II Trial of Treatment With Cisplatin and Pemetrexed or Cisplatin and Oral Vinorelbine in Chemotherapy Naïve Patients Affected by Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer With High Thymidylate Synthase Expression	P2	terminated	2	Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS	Mar 2016
NCT02585388	CHEOPS	Addition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer.	P2	terminated	120	ARCAGY/ GINECO GROUP	Oct 2015
NCT01104259		Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer	P1	completed	50	University of Washington	Jul 2010
NCT01271725		LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures	P2	completed	74	Boehringer Ingelheim	May 2011
NCT00003622		Vinorelbine Plus Paclitaxel in Treating Patients With Metastatic Prostate Cancer That Is Refractory to Hormone Therapy	P2	withdrawn	0	James Ahlgren	Jan 1999
NCT00381940		Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy	P2	completed	26	National Cancer Institute (NCI)	Jan 2007
NCT02985658		Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer	—	no longer available	0	University of Washington	—
NCT02940990		SBRT in Multi-metastatic NSCLC Patients Which Are Pan-negative for Driver Mutations	P2	unknown	50	Shanghai Chest Hospital	Nov 2016
NCT01520103	VicTORia	Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer	P2	completed	139	AIO-Studien-gGmbH	Jan 2012
NCT00755170		Metronomic Vinorelbine and Bevacizumab in Patients With Non Small Cell Lung Cancer	P2	completed	48	Hellenic Oncology Research Group	Nov 2008
NCT01884441		Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients	P2	unknown	59	Armando Santoro, MD	Jul 2011
NCT02768415		Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast Cancer	P2	unknown	40	Chinese Academy of Medical Sciences	Jun 2016
NCT01029678	RACCOSA	Concomitant Radio-chemotherapy in the Elderly	P2	completed	48	University Hospital, Limoges	Jan 2010
NCT01454934		A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer	P3	completed	540	Eisai Inc.	Dec 2011
NCT00920153		Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma	P3	terminated	442	French Innovative Leukemia Organisation	May 2008
NCT01013740	VITAL	Lapatinib in Combination With Vinorelbine	P2	completed	112	Novartis Pharmaceuticals	Nov 2009
NCT01784549	CONTEST	Customized Neoadjuvant Versus Standard Chemotherapy in NSCL Patients With Resectable Stage IIIA (N2)Disease	P2	unknown	168	IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy	Jul 2012
NCT02319577		GEfitinib Plus viNOrelbine in Advanced EGFR Mutated NSCLC. GENOA Trial	P2	unknown	80	IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy	Mar 2012
NCT01884428		Study of Combination of PIGEV Before Autologous Stem Cell Transplant in Patients With Hodgkin's Lymphoma	P1	unknown	24	Armando Santoro, MD	Jul 2011
NCT01565083	VELVET	A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer	P2	completed	213	Hoffmann-La Roche	Apr 2012
NCT00868634	CARIN	Capecitabine and Bevacizumab ± Vinorelbine in Metastatic Breast Cancer	P3	completed	600	iOMEDICO AG	Feb 2009
NCT02544243		Vinorelbine/Gemcitabine Versus Vinorelbine/Cisplatin in Metastatic Breast Cancer	P2	unknown	200	Shandong Cancer Hospital and Institute	Sep 2015
NCT01126138	NX	Capecitabine (NX) Versus Docetaxel Plus Capecitabine (TX) as 1-line Chemotherapy on Metastatic Breast Cancer (MBC)	P3	unknown	200	Chinese Academy of Medical Sciences	Jul 2010
NCT01222715		Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma	P2	completed	87	National Cancer Institute (NCI)	Oct 2010
NCT02497118		Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLC	P4	completed	30	Tianjin Medical University Cancer Institute and Hospital	Aug 2010
NCT01007942	BOLERO-3	Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer	P3	completed	569	Novartis Pharmaceuticals	Oct 2009
NCT01443078	NEOSCAN	Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)	P2	completed	42	Memorial Sloan Kettering Cancer Center	Oct 2011
NCT01941771	XeNa	Phase II Trial With Metronomic, Capecitabine Plus Oral Vinorelbine for Metastatic Breast Cancer	P2	completed	110	University of Aarhus	Jun 2012
NCT01325428	BIBW2992	Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer	P2	completed	26	Boehringer Ingelheim	Aug 2011
NCT00686959	PROCLAIM	Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer	P3	completed	598	Eli Lilly and Company	Sep 2008
NCT01196559		Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Ovarian Cancer	P2	completed	44	The Catholic University of Korea	Jan 2011
NCT01242449	OVINTRA	Oral Vinorelbine in Combination With Trastuzumab for Metastatic Breast Cancer	P2	completed	10	Vejle Hospital	Nov 2010
NCT00337194		SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma	P2	completed	30	National Cancer Institute (NCI)	Apr 2006
NCT01441596	HER2	Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases	P2	completed	121	Boehringer Ingelheim	Oct 2011
NCT00602797		Vinorelbine Tartrate and Paclitaxel in Treating Older Patients With Advanced Non-Small Cell Lung Cancer	P2	completed	20	University of Nebraska	Dec 2007
NCT01238029	CELAVIE	Dose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast Cancer	P1	terminated	12	Sponsor GmbH	Oct 2010
NCT01161368		A Study Evaluating the Efficacy and Safety of Lapatinib + Vinorelbine in ErbB2 Positive Metastatic Breast Cancer Patients	P2	terminated	9	Central European Cooperative Oncology Group	Sep 2010
NCT01155258		Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors	P1	completed	19	University of Southern California	Jun 2010
NCT00828074		Sorafenib and Vinorelbine in Treating Women With Stage IV Breast Cancer	P1/P2	completed	46	City of Hope Medical Center	Nov 2008
NCT00349089		Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy	P2	completed	132	Thoraxklinik-Heidelberg gGmbH	Sep 2006
NCT01038037	Lung-TRIO	First-Line Chemotherapy and Panitumumab in Advanced Non-Small Cell Lung Cancer	P2	terminated	23	Vejle Hospital	Jan 2010
NCT00499109		Phase III of RRM1 & ERCC1 Directed Customized Chemotherapy for the Treatment of Patients With NSCLC	P3	completed	275	H. Lee Moffitt Cancer Center and Research Institute	May 2007
NCT00462787		Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Leukemia	P1	completed	23	Memorial Sloan Kettering Cancer Center	Apr 2007
NCT01220375	PAV	PAV-trial: Plerixafor and Chemotherapy With Vinorelbine for Stem Cell Mobilization in Patients With Myeloma	P2	completed	44	Insel Gruppe AG, University Hospital Bern	Apr 2010
NCT01531764		BIBW 2992 (Afatinib) and Vinorelbine	P2	terminated	2	University of Magdeburg	Jul 2012
NCT01060514	NSCLC	Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer	P1	terminated	8	Northwestern University	Feb 2010
NCT00870532		Study of Combination of Metronomic Oral Vinorelbine and Sorafenib in Patients With Advanced Non-small Cell Lung Cancer	P1	completed	52	National Cancer Centre, Singapore	Jun 2008
NCT00455572		Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer	P1	terminated	71	GlaxoSmithKline	May 2007
NCT01528826	NVBOX	Salvage Chemotherapy of Vinorelbine Plus Oxaliplatin in Metastatic Triple-negative Breast Cancer:a Prospective Trial	P2	unknown	35	Fudan University	Dec 2011
NCT00842712	CERTO	Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC)	P2	completed	232	Merck KGaA, Darmstadt, Germany	Feb 2009
NCT01684111	VENUS-1	An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Vinorelbine in Elderly Patients With Advanced Non Small Lung Cell Cancer - Stage IV (VENUS-1)	P1	completed	7	Aktion Bronchialkarzinom e.V.	Jun 2013
NCT00392691		Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment	P1	completed	20	Swiss Cancer Institute	Oct 2006
NCT00093808		Capecitabine, Vinorelbine, and Trastuzumab in Treating Patients With Metastatic Breast Cancer	P2	completed	47	Alliance for Clinical Trials in Oncology	Aug 2004
NCT01214616		BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid Tumours	P1	completed	17	Boehringer Ingelheim	Oct 2010
NCT01683682	VENUS-2	An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Carboplatin and Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer - Stage IV (VENUS-2)	P1	completed	8	Aktion Bronchialkarzinom e.V.	Apr 2013
NCT00795678		Chemotherapeutic Agents in Brain/Breast	—	completed	10	Case Comprehensive Cancer Center	Sep 2008
NCT03887130		Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer	P2	completed	152	Pierre Fabre Medicament	Mar 2007
NCT00906698		Afatinib and Vinorelbine in Tumours Known to Overexpress EGFR and/or HER2	P1	completed	55	Boehringer Ingelheim	Jun 2009
NCT00670982		Bevacizumab in Combination With Vinorelbine and Trastuzumab for HER2-Positive, Metastatic Breast Cancer	P2	completed	29	Harold J. Burstein, MD, PhD	May 2008
NCT00193921		Chemoradiotherapy in Patients With Localised Lung Cancer	P2	completed	82	Trans Tasman Radiation Oncology Group	Feb 2003
NCT00863512		Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer	P3	terminated	34	Alliance for Clinical Trials in Oncology	Mar 2009
NCT00015938	S0102	S0102: Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer	P2	completed	95	SWOG Cancer Research Network	May 2001
NCT00724386	GCSF	Concomitant Chemoradiotherapy With Weekly Paclitaxel and Vinorelbine and Granulocyte Colony Stimulating Factor (GCSF) Support in Patients With Advanced Breast Cancer	P1	completed	26	University of Chicago	Jun 1999
NCT00881387		Rituximab, Gemcitabine, and Vinorelbine in Treating Patients With Hodgkin Lymphoma That Has Relapsed or Not Responded to Treatment	P2	withdrawn	0	University of Miami	Feb 2009
NCT00702182		Study of Oral Vinorelbine and Erlotinib in Non-Small Cell Lung Cancer	P1	completed	30	National Cancer Centre, Singapore	Apr 2008
NCT01109524		Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer	P2	completed	72	Eli Lilly and Company	Jul 2010
NCT00256282		Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma	P2	completed	52	John P. Fruehauf	Apr 2003
NCT00372476	INV181	Efficacy and Safety of Imatinib and Vinorelbine in Patients With Advanced Breast Cancer	P4	completed	33	Novartis Pharmaceuticals	Jun 2006
NCT00709618		Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects	P2	terminated	44	GlaxoSmithKline	Jun 2008
NCT00148798	FLEX	Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX)	P3	completed	1,861	Merck KGaA, Darmstadt, Germany	Oct 2004
NCT00513058		Lapatinib and Vinorelbine in Treating Women With HER2-Overexpressing Locally Advanced or Metastatic Breast Cancer	P1	completed	33	UNICANCER	Jun 2007
NCT01128543		Lapatinib in Combination With Vinorelbine	P2	completed	29	GlaxoSmithKline	Apr 2009
NCT00006760		Combination Chemotherapy in Treating Children With Refractory or Relapsed Hodgkin's Lymphoma	P2	completed	66	Children's Oncology Group	May 2001
NCT00675597		Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer	N/A	completed	25	Memorial Sloan Kettering Cancer Center	May 2008
NCT01020864	CECAVI	Cetuximab in Combination With Chemotherapy for Patients With Head and Neck Cancer	P2	withdrawn	0	Per Pfeiffer	Jan 2010
NCT00545948	TOP0703	Adjuvant Cisplatin With Either Genomic-Guided Vinorelbine or Pemetrexed for Early Stage Non-Small-Cell Lung Cancer	P2	terminated	31	Duke University	Dec 2007
NCT00041067		S0215 Trastuzumab, Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer	P2	completed	76	SWOG Cancer Research Network	Sep 2002
NCT00764972		Phase IB/II Trial Combining Vinorelbine With Sorafenib as First-Line Treatment in Patients With Metastatic Breast Cancer	P1/P2	unknown	36	McGill University	Oct 2007
NCT00298415	NSCLC	Chemotherapy of Elderly Patients With Non-Small-Cell Lung Cancer (NSCLC)	P3	completed	451	Intergroupe Francophone de Cancerologie Thoracique	Mar 2006
NCT00389922		Lapatinib and Vinorelbine in Treating Patients With Advanced Solid Tumors	P1	completed	22	University of California, Davis	Dec 2005
NCT01254136		Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer	P1/P2	terminated	20	Incyte Corporation	Oct 2010
NCT01050322	GLICO-0801	Safety Study in Subjects With Metastatic Breast Cancer Who Progressed After Taxanes Treatment.	P2	completed	142	Latin American Cooperative Oncology Group	Nov 2009
NCT00705549		Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer	P2	terminated	88	Hellenic Oncology Research Group	Feb 2008
NCT00503750		Phase II Neoadjuvant Trial of Trastuzumab in Combination With Dose-Dense ABI-007 (Abraxane™)	P2	completed	27	Emory University	Apr 2008
NCT00194792		Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer	P2	terminated	28	University of Washington	Aug 2005
NCT00194779		Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery	P2	completed	50	University of Washington	Oct 2003
NCT00476827		A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain	P2	terminated	16	Duke University	May 2007
NCT00908869	METRO1	Combination of Continuous Low Doses of Vinorelbine, Cyclophosphamide and Interferon Alpha 2b (" Metronomic Chemotherapy ") for Antiangiogenic and Antivascular Effect. Trial With Pharmacodynamic Study in Adult Advanced Neoplasm	P1	completed	30	Institut Paoli-Calmettes	May 2006
NCT00754702		Vinorelbine Metronomic Plus Lapatinib for Overexpressing HER-2 Metastatic Breast Cancer	P2	terminated	16	University Hospital of Crete	Oct 2008
NCT00477035	CIK	Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies	P1	completed	22	Sally Arai	May 2006
NCT00194727		Weekly Vinorelbine and Oral Capecitabine as Treatment for Stage IV Breast Cancer	P2	completed	40	University of Washington	May 2002
NCT01220284		Satraplatin and Vinorelbine in Advanced Solid Tumors	P1	unknown	27	Southern Europe New Drug Organization	Feb 2008
NCT00737867		Vinorelbine/Gemcitabine Versus Vinorelbine/Carboplatin in Advanced Non-small Cell Lung Cancer	P3	completed	444	The Norwegian Lung Cancer Study Group	Sep 2007
NCT00629148	MBC	Sequential Versus Simultaneous Use of Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer (MBC)	P2	completed	60	Fudan University	Aug 2007
NCT01196078		A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer	P4	completed	114	Hoffmann-La Roche	Feb 2007
NCT00235235		A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer	—	terminated	80	Hoosier Cancer Research Network	Sep 2005
NCT00434668	TOLEDO	Evaluation of Tolerability of Adjuvant Cisplatin/Docetaxel in Completely Resected Stage IB/II Non-Small Cell Lung Cancer	P2	completed	99	University Hospital, Antwerp	Dec 2005
NCT00773188		A Feasibility Trial of Avastin (Bevacizumab) in Combination With Concomitant Chemoradiation (Cisplatin and Vinorelbine) in Patients With Locally Advanced Non-Squamous Non-Small Cell Lung Cancer.	P1	completed	6	Hoffmann-La Roche	Dec 2008
NCT00388349		Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease	P2	completed	146	Stanford University	Sep 2001
NCT00325234		Pemetrexed-Carboplatin and Gemcitabine-Vinorelbine in Advanced Breast Cancer	P2	completed	135	Eli Lilly and Company	Jun 2006
NCT00088530	NHL	BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)	P3	completed	140	CTI BioPharma	Jul 2004
NCT00842595		Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive Lymphomas	P2	completed	50	French Innovative Leukemia Organisation	Dec 2003
NCT00540982		Vinorelbine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Treatment and Liver Dysfunction	P1/P2	completed	47	City of Hope Medical Center	Feb 1997
NCT00958724		Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors	P1	completed	6	Puma Biotechnology, Inc.	Jul 2009
NCT00620971		Cisplatin/Vinorelbine/Bevacizumab Followed by Docetaxel/Gemcitabine/Bevacizumab Versus the Cisplatin/Docetaxel/Bevacizumab Combination in Locally Advanced or Metastatic NSCLC	P2	completed	77	Hellenic Oncology Research Group	Jan 2008
NCT00636311		A Phase II Study of IGEV +/- Bortezomib Before Hign Dose Consolidation in Relapsed/Refractory Hodgkin's Lymphoma	P2	completed	13	Istituto Clinico Humanitas	Feb 2008
NCT00597116		An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma	P2	terminated	25	Genzyme, a Sanofi Company	Dec 2007
NCT00287963		Topotecan and Vinorelbine in Treating Patients With Recurrent Lung Cancer	P1	completed	18	Medical University of South Carolina	Feb 2004
NCT00694200		Vinorelbine Metronomic Plus Bevacizumab as Salvage Therapy for Breast Cancer	P2	terminated	13	Hellenic Oncology Research Group	Apr 2008
NCT00253591		Radiation Therapy With or Without Vinorelbine and Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer	P2/P3	completed	500	Medical Research Council	Jun 2005
NCT00002583		Vinorelbine + Cisplatin or No Further Therapy in Non-small Cell Lung Cancer That Has Been Surgically Removed	P3	completed	482	NCIC Clinical Trials Group	Jul 1994
NCT00801151		Vorinostat in Combination With Vinorelbine in Patients With Advanced Cancer	P1	terminated	30	Institut Claudius Regaud	Jan 2009
NCT01687439	NSCLC	Effect of Endostar Combined With Chemotherapy and Radiotherapy on Blood Vessels and Microenvironment of Tumor for Non-small Cell Lung Cancer (NSCLC)	P2	completed	15	Fudan University	Dec 2008
NCT00215930		The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer	P2	completed	53	H. Lee Moffitt Cancer Center and Research Institute	Feb 2004
NCT00088985		Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Women With Locally Recurrent or Metastatic Breast Cancer	P2	terminated	56	UNC Lineberger Comprehensive Cancer Center	Jan 2004
NCT00176488		Epirubicin and Vinorelbine in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer	P2	terminated	31	University of Medicine and Dentistry of New Jersey	Jun 2003
NCT01097317		First-Line Chemotherapy With or Without Neuromuscular Electrical Stimulation in Treating Patients With Non-Small Cell Lung Cancer	P2	unknown	52	Wales Cancer Trials Unit	Sep 2009
NCT00272558		Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma	P2	completed	40	Rigshospitalet, Denmark	Sep 2004
NCT00193089		Docetaxel, Vinorelbine and Trastuzumab in the Treatment of Patients With Metastatic Her-2 Positive Breast Cancer	P2	completed	60	SCRI Development Innovations, LLC	Apr 2001
NCT01209520	NSCLC	Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy	N/A	completed	6	University of Miami	Jul 2009
NCT00706069		Vinorelbine Oral Plus Capecitabine Combination In Metastatic Breast Cancer	P1	completed	40	Hellenic Oncology Research Group	Jun 2008
NCT00130507		Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab	P2	terminated	14	Spanish Breast Cancer Research Group	Nov 2005
NCT00354393		Combination Chemotherapy With or Without Surgery & Chemoradiotherapy in Patients With Malignant Pleural Mesothelioma	P2	completed	9	The Cleveland Clinic	Aug 2002
NCT00169104	G-CSF	Effects of Granulocyte Colony-stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function	P2/P3	terminated	23	Dartmouth-Hitchcock Medical Center	Jul 2002
NCT00401609	G-Step	G-Step: Gemcitabine Based Small-cell Lung Cancer Treatment in Elderly Patients	P1/P2	completed	85	National Cancer Institute, Naples	Nov 2000
NCT00431106		Vinorelbine and Gemcitabine Versus Capecitabine in Pretreated Metastatic Breast Cancer	P3	completed	144	Hellenic Oncology Research Group	Apr 2002
NCT00430001		Vinorelbine Plus (+) Trastuzumab vs Docetaxel Plus (+) Trastuzumab as 1 Line Treatment for HER2 Positive (+) Metastatic Breast Cancer	P3	unknown	300	Danish Breast Cancer Cooperative Group	May 2005
NCT00641160		Safety Study of Oral Vinorelbine in Subjects With Non-Hematologic Malignancies	P1	unknown	12	Metronome Therapeutics	Mar 2008
NCT00453635		Study With Docetaxel, Carboplatin and Herceptin Versus Vinorelbine and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients	P2	terminated	88	Hellenic Oncology Research Group	Dec 2003
NCT00026156	S0027	S0027: Vinorelbine Followed by Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer	P2	completed	125	SWOG Cancer Research Network	Nov 2001
NCT00079287		Vinorelbine, Gemcitabine, and Docetaxel Compared With Paclitaxel and Carboplatin in Treating Patients With Advanced Non-Small Cell Lung Cancer	P3	completed	0	Japan Multinational Trial Organization	Mar 2001
NCT01839032		Oral Vinorelbine as Induction Chemotherapy Followed Concomitant Chemoradiotherapy	P2	completed	70	Pierre Fabre Medicament	May 2005
NCT00041470		Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial	P1/P2	terminated	38	University of Washington	Mar 2001
NCT00736814		First-Line Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery	P2	unknown	117	Yonsei University	Jun 2008
NCT00057798		Genetic Changes in Patients With Non-Small Cell Lung Cancer Who Are Receiving Vinorelbine and Gemcitabine Before Surgery	P2	completed	21	Roswell Park Cancer Institute	Mar 2000
NCT00345059	DISTAL-2	The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer	P3	terminated	84	National Cancer Institute, Naples	May 2005
NCT00026494		Temozolomide and Vinorelbine in Treating Patients With Recurrent Brain Metastases	P1/P2	completed	49	Memorial Sloan Kettering Cancer Center	Jul 2001
NCT00278070		Metronomic Oral Vinorelbine in Patients With Metastatic Tumors	P2	completed	0	Hellenic Cooperative Oncology Group	Jan 2006
NCT00140140		A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer	P1/P2	terminated	16	Celgene	Aug 2005
NCT00441740		Randomized Trial With Vinorelbine and Gemcitabine Versus Docetaxel and Gemcitabine in Patients With Non-Small Cell Lung Cancer	P3	completed	419	Hellenic Oncology Research Group	Apr 2004
NCT00163761		Efficacy Study of Outpatient Therapy for Lymphoma	P2	completed	90	Bayside Health	Dec 2002
NCT00441922	NSCLC	Trial of Docetaxel Versus Vinorelbine as 1st Line Treatment in Elderly Patients With Non-Small-Cell Lung Cancer (NSCLC)	P3	completed	166	Hellenic Oncology Research Group	Jan 2003
NCT00128310		Vinorelbine Versus Gemcitabine Plus Vinorelbine in Metastatic Breast Cancer Patients	P3	completed	252	Spanish Breast Cancer Research Group	Jan 2001
NCT00432562		A Bioequivalence Study of Vinorelbine Tartrate Injectable Emulsion in Patients With Advanced Cancer.	P1	completed	31	Mast Therapeutics, Inc.	Feb 2007
NCT00403988		Vinorelbine and Oxaliplatin (Vinox) With or Without Trastuzumab (Herceptin®) in Advanced Breast Carcinoma	P2	terminated	40	American University of Beirut Medical Center	Jun 2004
NCT00146549		Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Patients With Metastatic Breast Cancer	P3	completed	250	Dana-Farber Cancer Institute	Aug 2001
NCT00165334		Cetuximab and Vinorelbine in Elderly Subjects With Lung Cancer	P2	completed	53	Dana-Farber Cancer Institute	Jun 2005
NCT00280878		Rituximab in Combination With Outpatient Therapy for CD20+ Lymphoma	P2	completed	12	Bayside Health	Jan 2006
NCT00193362		Study of Paclitaxel, Carboplatin, and Gemcitabine Versus Gemcitabine and Vinorelbine for Non-Small Cell Lung Cancer	P3	completed	200	SCRI Development Innovations, LLC	Jun 2004
NCT00022152		Vinorelbine in Treating Older Women With Stage IV Breast Cancer	P2	completed	25	Alliance for Clinical Trials in Oncology	Nov 2001
NCT00008333		Vinorelbine in Treating Older Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer	P2	completed	59	Alliance for Clinical Trials in Oncology	Apr 2001
NCT00295672	VINCR	Oral Vinorelbine and Cisplatin and Concurrent Radiotherapy After Induction Chemotherapy in Locally Advanced NSCLC.	P2	completed	60	University Hospital, Brest	Feb 2006
NCT00192062		A Trial of Gemcitabine Combined With Vinorelbine as First Line Chemotherapy for Metastatic Breast Cancer	P2	completed	80	Eli Lilly and Company	Jul 2004
NCT00134641		Study of Gemcitabine and Vinorelbine in Soft Tissue Sarcomas	P2	completed	40	Dana-Farber Cancer Institute	Feb 2003
NCT00005865		Vinorelbine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer	P2	completed	0	GlaxoSmithKline	Apr 2000
NCT00194740		Taxotere Plus Weekly Navelbine and G-CSF: A Study in Stage IV Breast Cancer	P2	completed	48	University of Washington	Nov 1997
NCT00003159		Surgery With or Without Preoperative Chemotherapy in Treating Patients With Resectable Non-small Cell Lung Cancer	P3	completed	600	Medical Research Council	Aug 1997
NCT00496275		Phase I Combination With Vinorelbine or Gemcitabine Plus Cisplatin in Locally Advanced or Metastatic NSCLC	P1	completed	17	Genzyme, a Sanofi Company	Aug 2006
NCT01439191		Study of Cipterbin®, Used Alone or With Vinorelbine in Patients With HER2/Neu-overexpressed Metastatic Breast Cancer	P2	completed	109	Shanghai CP Guojian Pharmaceutical Co., Ltd.	Jul 2005
NCT00401492	MILES-02	MILES-02: Study of Chemotherapy Treatment and Toxicity in Elderly Patients With Advanced Non Small Cell Lung Cancer	P2	completed	159	National Cancer Institute, Naples	Jun 2002
NCT00003234		Vinorelbine in Treating Children With Recurrent or Refractory Cancers	P2	completed	50	Children's Oncology Group	May 1998
NCT00006029		Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma	P1/P2	completed	91	Alliance for Clinical Trials in Oncology	Jul 2000
NCT00003587	S9806	S9806: Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer	P2	completed	204	SWOG Cancer Research Network	Oct 1998
NCT00401427	HERVIN	HERVIN: Trastuzumab and Vinorelbine in Metastatic Breast Cancer	P2	completed	50	National Cancer Institute, Naples	Nov 2002
NCT00168883	NSCLC	Study for Patients With Non Small Cell Lung Cancer (NSCLC)	P2	unknown	80	Charite University, Berlin, Germany	Oct 2002
NCT00198432		Chemoradiotherapy of NSCLC Stage IIIB	P2	completed	130	Intergroupe Francophone de Cancerologie Thoracique	Mar 2002
NCT00532623		Phase II Study of Gemcitabine/Vinorelbine vs Sequential Gemcitabine Followed by Vinorelbine in Metastatic Breast Cancer	P2	completed	82	National Cancer Center, Korea	May 2004
NCT00271271	GON	Efficacy Study of GEMOX Combination and Vinorelbine in NSCL Patients	P2	completed	40	Sanofi	Jun 2003
NCT00627354		Mitoxantrone, Etoposide, and Vinorelbine As Second-Line Therapy in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy	P2	completed	90	Groupe D'Etude des Tumeurs Uro-Genitales	Sep 2006
NCT00225173		Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease	P2	terminated	45	Stanford University	Oct 2001
NCT00151086		Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer	P1/P2	completed	33	University of Michigan Rogel Cancer Center	Dec 2001
NCT00379457		Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma	P3	unknown	600	European Paediatric Soft Tissue Sarcoma Study Group	Jun 2006
NCT00678964	TIE	Erlotinib Versus Carboplatin/Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)	P2	unknown	260	LungenClinic Grosshansdorf	Jun 2006
NCT00103233		Vinorelbine With or Without Trastuzumab in Treating Women With Progressive Metastatic Breast Cancer	P3	completed	0	SWOG Cancer Research Network	Dec 2004
NCT00277069		Phase I-II Study of Carboplatin, Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer	P1/P2	completed	33	University of New Mexico	May 2000
NCT00256711	INVITE	Phase II Iressa Versus Vinorelbine (INVITE)	P2	completed	192	AstraZeneca	Jul 2004
NCT00333294		Phase II Iressa + Irradiation Followed by Chemo in NSCLC	P2	completed	50	AstraZeneca	Sep 2004
NCT00265694		Random Trial for Elderly Patients With NSCLC	P3	unknown	0	Inje University	—
NCT00309998		Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer	P2	completed	50	University of Rochester	Sep 2005
NCT00003902		Capecitabine and Vinorelbine in Treating Older Women Who Have Metastatic Breast Cancer With or Without Bone Involvement	P1/P2	completed	110	Swiss Cancer Institute	Mar 1999
NCT00004237		Comparison of Three Combination Chemotherapy Regimens in Treating Women With Stage I or Stage II Breast Cancer	P2	completed	0	Royal Marsden NHS Foundation Trust	Oct 1998
NCT00215462		Vinorelbine in Unresectable or Metastatic Esophageal and Gastric Adenocarcinoma	P2	completed	32	Dana-Farber Cancer Institute	Jun 2000
NCT00683514		Oral Chemotherapy And Platinum With Radiotherapy Followed Or Not By Consolidation With The Same Chemotherapy In Locally Advanced Non Small Cell Lung Cancer	P3	completed	201	Pierre Fabre Medicament	Apr 2005
NCT00083083		Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer	P2	unknown	250	American College of Radiology Imaging Network	Mar 2005
NCT00075673		Vinorelbine and Celecoxib in Treating Women With Relapsed or Metastatic Breast Cancer	P1	terminated	6	Case Comprehensive Cancer Center	Nov 2003
NCT00006372		Combination Chemotherapy in Treating Patients With Advanced Solid Tumors	P1	completed	10	Case Comprehensive Cancer Center	Feb 2000
NCT00003963		Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell Transplantation	P2	completed	14	Jonsson Comprehensive Cancer Center	May 1999
NCT00054197		Polyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer	P3	terminated	0	CTI BioPharma	Jan 2003
NCT00070304		Gemcitabine and Vinorelbine in Treating Young Patients With Recurrent or Refractory Hodgkin's Lymphoma	P2	completed	33	Children's Oncology Group	Jul 2004
NCT00003828	S9804	S9804: Vinorelbine in Treating Patients With Stage IV Melanoma	P2	completed	24	SWOG Cancer Research Network	May 1999
NCT00017459		Cisplatin Plus Vinorelbine With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer	P3	completed	0	Sanofi	Jul 2000
NCT00163748		Efficacy and Treatment Related Toxicity Study of a New Regimen for Lymphoma	P2	completed	40	Bayside Health	Feb 2001
NCT00159094		A Trial of Doxil and Multiday Vinorelbine in Patients With Metastatic Breast Cancer	P2	unknown	30	Hematology Oncology Consultants	Oct 2003
NCT00075699		Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma	P3	completed	840	Medical Research Council	Sep 2003
NCT00180947		Study of Vinorelbine and Cyclofosfamide Among Patients With Refractory Tumours or in Relapse	P2	unknown	210	Gustave Roussy, Cancer Campus, Grand Paris	Jun 2003
NCT00042315	NSCLC	A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Vinorelbine as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC)	P3	terminated	490	QLT Inc.	Jun 2002
NCT00055887		Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer	P3	withdrawn	0	Spectrum Pharmaceuticals, Inc	Nov 2002
NCT00480597		Gemcitabine/Vinorelbine Versus Gemcitabine/Cisplatin Versus Gemcitabine/Capecitabine in Metastatic Breast Cancer	P2	completed	141	Ludwig-Maximilians - University of Munich	Oct 2002
NCT00049660		Capecitabine Compared With Vinorelbine in Treating Women With Metastatic Breast Cancer	P2/P3	terminated	47	European Organisation for Research and Treatment of Cancer - EORTC	Sep 2002
NCT00004096		Carboplatin Plus Vinorelbine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer	P1/P2	completed	0	Northwestern University	Aug 1999
NCT00004093		Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer	P1/P2	terminated	36	Northwestern University	Aug 1999
NCT00006682		Vinorelbine and Docetaxel in Treating Women With Metastatic Breast Cancer	P2	completed	0	Medstar Health Research Institute	Feb 2000
NCT00001944		Vinorelbine and XR9576 to Treat Cancer	P1	completed	30	National Cancer Institute (NCI)	Dec 1999
NCT00002949		Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis	P1	completed	33	University of Chicago	Jul 1996
NCT00005847		Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy	P2	completed	0	Eastern Cooperative Oncology Group	Apr 2001
NCT00017394		Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast Cancer	P2	completed	56	National Cancer Institute (NCI)	Mar 2001
NCT00003584		Combination Chemotherapy With or Without Prednisone in Treating Patients With Recurrent and/or Metastatic Kidney Cancer	P2	completed	35	University of New Mexico	Jul 1998
NCT00030459		Palliative Therapy With or Without Chemotherapy in Treating Patients With Malignant Mesothelioma	P2	unknown	0	British Thoracic Society	Nov 2000
NCT00006088		Vinorelbine in Treating Patients With Metastatic or Advanced Solid Tumors	P1	unknown	0	H. Lee Moffitt Cancer Center and Research Institute	Jun 2000
NCT00005838		Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery	P3	completed	756	National Cancer Institute (NCI)	Mar 2000
NCT00003400		Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer	P2	completed	45	University of Maryland, Baltimore	Sep 1998
NCT00014430		Chemotherapy Plus Trastuzumab in Treating Patients With Breast Cancer	P1	completed	13	Dartmouth-Hitchcock Medical Center	Nov 1999
NCT00006215		Docetaxel and Vinorelbine Plus Filgrastim in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer	P2	unknown	0	Amgen	Oct 1999
NCT00003259		Vinorelbine in Treating Patients With Metastatic Prostate Cancer	P2	completed	40	Swiss Cancer Institute	Oct 1997
NCT00148291		Phase III Study of Docetaxel Vs Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer	P3	completed	180	West Japan Thoracic Oncology Group	Jun 1999
NCT00006114		Combination Chemotherapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy	P2	unknown	0	GERCOR - Multidisciplinary Oncology Cooperative Group	May 1999
NCT00003730		Vinorelbine Plus Fluorouracil in Treating Women With Metastatic Breast Cancer	N/A	completed	80	European Organisation for Research and Treatment of Cancer - EORTC	Dec 1998
NCT00004100		Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer	P3	unknown	0	Istituto Nazionale per lo Studio e la Cura dei Tumori	Nov 1998
NCT00004105		Combination Chemotherapy in Treating Patients With Advanced Cancer	P1/P2	completed	0	NYU Langone Health	Sep 1998
NCT00005825		Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer	P2	unknown	0	Raghu Nandan, M.D., Inc	Sep 1998
NCT00003447		Vinorelbine and/or Gemcitabine in Treating Older Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer	P3	unknown	630	Istituto Nazionale per lo Studio e la Cura dei Tumori	Jul 1998
NCT00002813		Combination Chemotherapy in Treating Patients With Recurrent or Refractory Cervical Cancer	P2	completed	62	Gynecologic Oncology Group	Aug 1997
NCT00003240		Standard Therapy Given With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer	P3	unknown	1,800	National Cancer Institute (NCI)	Oct 1995
NCT00002887		Hydroxyurea Plus Combination Chemotherapy in Patients With Non-small Cell Lung Cancer	P1	unknown	30	Ottawa Regional Cancer Centre	Jul 1995
NCT00002823		Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer	P3	completed	3,300	Gustave Roussy, Cancer Campus, Grand Paris	Feb 1995

Vinorelbine clinical trials: frequently asked questions

How many Vinorelbine clinical trials are there?: 426 Vinorelbine clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 30 are actively recruiting participants. 214 are marked completed.
Are Vinorelbine clinical trials recruiting in 2026?: Yes — 30 Vinorelbine trials are actively recruiting in 2026, with 191 U.S. sites across 38 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Vinorelbine being studied for?: Vinorelbine is being studied for Breast Cancer, Lung Cancer, Metastatic Breast Cancer, Non Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung and 358 more. The trials are grouped by indication on this page.
What phase is Vinorelbine in?: Vinorelbine clinical trials span 7 Phase 4, 103 Phase 3, 225 Phase 2, 40 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Vinorelbine clinical trials?: The lead sponsor across the most Vinorelbine trials is Fudan University, with 222 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Vinorelbineas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed September 1, 2026.

Related pages on Hipa.ai:

Vinorelbine overview Vinorelbine evidence & publications